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Patients commonly present with a range of persistent throat symptoms. There is still much 
research to be done to understand how the individual symptoms relate to each other. An 
improved understanding of any symptom relationships could aid in identifying groups of 
patients for particular treatments. An opportunity to explore throat symptoms in detail was 
provided by a clinical trial to assess the effectiveness of stomach acid lowering medication on 
patients’ throat and voice complaints. The aim was to identify a clinically meaningful 
classification of patients’ symptoms. 
Methods 
Baseline data for all patients entering the Trial of Proton Pump Inhibitors in Throat 
Symptoms (TOPPITS) was provided by the Newcastle University Clinical Trials Unit. Data 
included: demographics, three separate symptom questionnaires and a scoring assessment of 
throat appearances. The relationships between patient demographics, symptom scores and 
throat appearances were explored with scatter plots and pairwise correlation. Exploratory 
factor analysis (EFA) of the combined symptom questionnaires was conducted. Cluster 
analysis of patients using the factors generated by the EFA was then performed. 
Results 
Data for 344 patients analysed. The distributions of the questionnaire scores were comparable 
with published literature. The total scores from the three questionnaires were positively 
related with each other. No relationship was observed between the throat appearances and 
any of the three symptom questionnaires in this population. The EFA led to a seven factor 
model comprising factors of: voice, cough, gastrointestinal symptoms, airway symptoms and 
dysphagia, throat clearing, life events, and lump in the throat sensation. Cluster analysis 
failed to identify clinically meaningful groups of patients. 
Conclusions 
The TOPPITS baseline data confirmed that patients recruited to the trial reflect the wider 
population of patients presenting with persistent throat symptoms. No evidence of an 
association between throat appearances and patient reported symptoms was found in this 
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study. Dimension reduction offered a simplified classification of symptoms, but clusters of 
patients based on this classification could not be identified. These results imply that 
individual throat symptoms cannot be used to define patient groups and that the term 
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Chapter 1 Introduction  
 
 Background  
“Persistent throat symptoms” comprise a group of interlinked complaints that include a hoarse 
voice, a feeling of a lump in the throat – often termed “globus” sensation, the need to clear 
one’s throat, mucus in the throat or catarrh, cough and throat discomfort. Patients with these 
symptoms are often referred to secondary care for assessment and management. In 2010, 
2.7million patients in England were referred to Ear, Nose and Throat (ENT) outpatient clinics 
for assessment of their medical symptoms[1]. In a study of over a thousand middle aged 
women, six percent reported a feeling of a lump in the throat[2]. In a similar sized, throat -
specific questionnaire study of all GP attenders to a single practice, 27% of patients reported 
abnormally high throat symptoms[3]. The author of this thesis, and colleagues, have 
suggested a conservative estimate of 60,000 patients referred each year to secondary care with 
persistent throat symptoms in England[4]. However, based on the data presented above and 
assuming five percent of the 2.7 million referrals have persistent throat symptoms, the 
estimate would be more than double, and closer to 135,000 referrals in England per year. 
Thus, management of these symptoms presents a significant burden to health care providers. 
Persistent throat symptoms have proven difficult to manage for both medical practitioners and 
patients.  Often there is no obvious underlying cause for the symptoms that can help target 
therapy.  As such, these complaints would reasonably fall into the category of “persistent 
physical symptoms”, which may have been included previously in terms such as “medically 
unexplained symptoms”. Patients with persistent throat symptoms are referred to ENT for a 
number of reasons; the main one being that specialist endoscopy of the larynx and pharynx is 
available. Most general practitioners (GPs) assessing these symptoms will recognise the 
chronic nature of the symptoms and often the intermittent occurrence of symptoms, and 
conclude that an underlying physical abnormality is unlikely. However, to rule out a treatable 
cause for the symptoms, endoscopy is required, and is usually only available in ENT or some 
speech and language therapy (SaLT) clinics.  Treatable causes for throat symptoms can 
usually be predicted by the nature of the symptoms.  For instance, voice quality which is 
always hoarse and does not fluctuate in nature is far more likely to be due to a physical, 
abnormal lesion on the vocal cord, than voice quality that varies in nature, for instance after 
talking for a period of time.  The latter is more likely to be “functional” in nature and theories 
postulate that tension or spasm in the muscles of the voice box may contribute to symptoms. 
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There is a known association between functional voice symptoms and psychological 
symptoms such as anxiety and perfectionism, and also with chronic fatigue[5]. These patients 
benefit from speech therapy delivered through specialist SaLT services[6]. 
In recent years the referral pattern of patients with persistent throat symptoms has changed.  
There has been increasing emphasis from the Department of Health (DoH) towards early 
referral for patients with symptoms that could suggest underlying malignancy. Given the 
vague nature of persistent throat symptoms, the difficulty in examining the throat well for 
GPs and the lack of a definable underlying cause for these symptoms, many patients are now 
referred on a two-week rule pathway; patients must be seen in specialist clinics within 
twoweeks of the GP referral.  The defined terms that should prompt such a referral are those 
of persistent hoarse voice, difficulty swallowing and pain in the throat. It is understandably 
difficult for GPs, who lack the ability to examine the throat, to separate chronic, perhaps 
“functional” type symptoms, from those that may be more concerning for an underlying throat 
cancer.  The DoH rightly wants more patients with cancer identified early to improve survival 
outcomes. One method to do this is to assess more patients urgently. The two-week-wait 
referral pathway has been recommended not just for patients who are felt to have cancer, but 
for patients whose symptoms may suggest cancer. The aim is to identify three percent of 
referrals who have an underlying cancer; symptoms that merit referral should have a 
minimum three percent positive predictive value in detecting cancer[7]. To do this requires 
seeing 97% of patients who do not. It is for this reason, that patients with persistent throat 
symptoms are now often referred to exclude cancer.   
 The symptoms 
There are a number of symptoms grouped together to form “persistent throat symptoms”, as 
defined for this thesis. There is no currently accepted terminology as such for these 
symptoms. Whilst the symptoms may sound distinct in nature, the reality is that there is 
significant overlap between them and highlighting one symptom over another by either the 
patient or clinician will have a large element of subjectivity associated to the labelling of the 
complaint. The most well-known “medically unexplained symptom” in the throat is that of “a 
feeling of a lump”, and has been noted to be reported by up to 45% of otherwise healthy 
people[8].  It is claimed[9] that the term globus hystericus was first described in 1707 by 
Purcell[10]; originating from the Latin globus meaning globe and hystericus presumably to 
indicate a psychological component to the symptom. It was later adopted into the Oxford 
English dictionary. Since then the symptom has been referred to as globus alone or globus 
pharyngeus[11]. Clinicians have sought physical explanations for the symptoms for many 
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years, suggesting amongst other causes: tightness of the upper oesophageal sphincter 
(cricopharyngeus), bony growths of the cervical spine, iron-deficiency anaemia, and more 
recently gastroesophageal reflux (GORD)[9].  
Recently, Doody and Fenton have questioned whether a more contemporary term should be 
adopted to describe globus pharyngeus[12]. They have suggested “troublesome throat 
awareness”, stating that a feeling of a lump in the throat on dry swallowing is a sensation that 
everyone can become aware of. Our research team has used the term “chronic throat 
symptoms”. However, having discussed this with an academic psychologist, we were 
recommended to use the term persistent throat symptoms, as a label more acceptable to 
patients. 
Whilst globus sensation has received the most interest, this may reflect that it is the medically 
unexplained symptom most connected to the throat. Rhinologists are well aware of the 
difficulty in managing catarrh or “post-nasal drip”[13], and pulmonologists have sought to 
define algorithms for managing chronic cough[14]. In the absence of identifiable underlying 
chronic sinusitis or chronic airways disease, these two symptoms may well overlap with 
globus. The repeated need to clear the throat is often associated with globus, but equally may 
occur with the sensation of mucus coming into the throat from the nose, and one person’s 
throat clearing is another person’s cough. Catarrh has been identified to be a general throat 
symptom, rather than being associated with either globus or difficulty swallowing[2].   
The link between persistent throat symptoms and psychological distress is well documented. 
Patients who complain of globus sensation report higher levels of anxiety and depression. The 
degree of distress caused by throat symptoms was found to be independently predicted by 
patients’ anxiety levels, in a study of 105 patients[2]. Patients with globus sensation reported 
higher rates of significant life events in the preceding year, than controls (for example 
relationship / marital breakdown). They also reported fewer confiding relationships with 
partners than controls[15]. Female patients with dysphonia reported higher levels of 
psychological distress and more medically unexplained symptoms than healthy controls and 
GP attenders[16]. In a study that included over 4000 male US veterans, 6.4% reported globus 
sensation. These patients tended to be from a lower socioeconomic background, and had an 
increased risk of being diagnosed with major depression, general anxiety, post-traumatic 
stress disorder and other persistent physical symptoms – when compared to patients who did 
not report globus[17]. 
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 Gastroesophageal reflux as a cause for chronic throat symptoms. 
The prevalence of gastroesophageal reflux disease (GORD) has been estimated at 10-20% of 
the Western World population, as defined by at least weekly heartburn or acid regurgitation, 
based on a systemic review of epidemiology studies in 2005[18]. The concept that backflow 
of stomach acid leads to throat symptoms, has been debated for over 30 years. In addition to 
the proposal that gastric acid damages the mucosa of the throat and voice, leading to 
symptoms, other causes have been set out such as the theory that gastric enzymes and bile 
acid, as components of the gastric refluxate, could directly damage the throat lining. In vivo 
experiments have demonstrated tissue level damage[19]. Cellular changes have been noted in 
response to individual and grouped components of gastric juice (acid, pepsin and bile) on 
laryngopharyngeal cells, with gene expression changes, immunohistochemical effects and 
changes in molecular regulator activity demonstrated[20]. Some of these cellular changes 
have also been demonstrated in laryngeal samples taken from patients with persistent throat 
symptoms[20]. 
The study most frequently cited to have popularised the theory that reflux of stomach contents 
leads to throat and voice symptoms was described by Koufman in 1991[21]. This paper 
introduced the term “silent reflux”; two hundred and twenty five patients with throat and 
voice symptoms underwent pH monitoring of the distal and upper oesophagus. Less than half 
complained of heartburn or acid regurgitation; hence over half were deemed to suffer with 
silent reflux. Sixty-two percent of all patients had abnormal oesophageal pH recordings. 
Hoarseness, globus and chronic cough were frequent symptoms in this patient population. 
Since then, Koufman and colleagues have publicised the theory, developed patient reported 
outcome measures [22] and a throat appearance scoring tool[23], and advocated the use of 
acid reduction medications in the form of proton-pump inhibitors (PPIs). ENT clinicians 
readily took up this theory as a treatment for hitherto resistant symptoms, with a survey in 
2007 of UK based otolaryngologists showing 90% believed in the condition and over 50% 
prescribed PPIs[24]. Multiple case series showed patients’ throat and voice symptoms 
responded over time with this treatment.  However, randomised clinical trials did not support 
the now widespread clinical practice, failing to demonstrate any benefit of PPIs over 
placebo[25]. 
In many ways analogous to chronic cough algorithms that advocated empirical trials of 
antihistamines, so patients with throat and voice symptoms started to be treated with empirical 
trials of PPIs; a practice often described in GP referral letters, with failure to respond 
seemingly justifying a specialist referral. Along with this practice came a term for the 
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condition – “Laryngopharyngeal Reflux”, or LPR. Other terms such as extraoesophageal 
reflux or supraoesophageal reflux have been used in the literature. 
The diagnosis of reflux as a cause for throat symptoms relies upon symptoms, signs, 
investigations and treatment outcomes. Many clinicians sceptical of LPR as an entity will cite 
the lack of coherence between the factors required to make the diagnosis. Symptoms and 
throat signs may correlate at presentation[26], although very little evidence exists in this area 
and the study cited included only 40 patients with a high rate of throat signs seen. 
Observational studies of large series of patients show that following treatment with PPIs, 
patients’ symptoms and throat appearances improved[27, 28]. Objective diagnostic tests, in 
particular oesophageal pH monitoring, have been used in a number of smaller observational 
studies to “diagnose” LPR by identifying abnormal acid exposure in the upper oesophagus 
over 24 hours. Some evidence does exists to demonstrate that acid can enter the throat; more 
reflux events and greater pharyngeal acid exposure times were recorded in the 
laryngopharynx of people with throat symptoms compared to asymptomatic controls in a 
large meta-analysis (n=793), using 24-ambulatory pH monitoring[29].  However, pH 
monitoring results do not appear to correlate with patients’ symptoms [30]. Finally, high 
quality evidence is lacking in support of PPIs to treat symptoms over and above offering a 
placebo effect. This does not mean that reflux does not play a role in throat symptoms, but 
reflects the reliance on PPIs in treating these patients and the vast bulk of research performed 
in this field relating to these medications. Very little evidence exists assessing the role of 
other factors which may reduce reflux, such as diet[31], alginates[32] and lifestyle[33].  
A recent literature search revealed six systematic reviews of randomised controlled trials, 
assessing the evidence for PPIs in throat symptoms [25, 34-38]. Most trials included were of 
less than 100 patients, with the largest study containing 145 patients. Overall the reviews do 
not demonstrate any improvement of symptoms with treatment over placebo, however two of 
the reviews specifically assessed the response in trials that reported the Reflux Symptom 
Index (RSI) and concluded that an improvement in pooled RSI scores was observed[34, 36]. 
It is clear from all of these studies that a significant placebo effect exists for this condition, as 
symptoms improved similarly in both the PPI and placebo groups.  
Reviewing the systematic reviews and meta-analyses of the trials assessing response to PPIs 
has caused some concern over the methodological rigour employed. Wei[36], as a sole author, 
concluded that PPI treatment could improve symptoms in patients with LPR. Within the text 
in figure 3, comparing the Reflux Symptom Index outcomes, is included a study by Shaheen 
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et al[39]. On closer examination of the original manuscript, this controlled trial did not collect 
the Reflux Symptom Index as an outcome. A recent electronic publication by Lechien et al 
[40]concluded a mild superiority of PPIs over placebo. Within their meta-analysis of placebo 
controlled trials is a trial by Ezzat et al[41], which compared a prokinetic agent and PPI 
versus PPI alone. We have contacted the authors to suggest this trial should not have been 
included in the stated meta-analysis as it assesses the role of the prokinetic agent and not the 
PPI. There remains a great interest in “LPR”, as evidenced by the popularity in prescribing 
patients PPIs for throat symptoms, and the ongoing publication of further meta-analyses. 
 The Trial of Proton Pump Inhibitors in Throat Symptoms 
Section 1.1 has described the clinical condition and background to patients with persistent 
throat symptoms. Section 1.2 will explain the basis behind the design of a large clinical trial, 
exploring the treatment of these symptoms. This clinical trial has provided the data utilised in 
the analysis for this thesis. Section 1.4 will describe the patient reported outcome measures 
used and the assessment used to examine the throat of patients. 
In 2011 the National Otolaryngology Trials Office, led by Professor Wilson, organised a 
conference entitled “Extraoesophageal Reflux – throat symptoms and cough: separating myth 
and evidence”[42].  I was invited to present an evidence synthesis at this meeting, 
summarising the use of alginates (eg. Gaviscon) and older formulations of stomach acid 
reduction medications.  Following the conclusions from this conference, a clinical research 
theme commenced. It was clear that the evidence was lacking to support the current practice 
of acid-reduction prescriptions for throat and voice symptoms. The organising team 
concluded that “studies assessing proton-pump inhibitors (PPIs) in extra-oesophageal reflux 
suffer from variable study design and quality, small numbers and heavy selection bias and use 
a variety of different treatment regimens”. A clinical trial was conceived with the Newcastle 
University Research Design Service in 2012, initially aiming to assess the clinical 
effectiveness of a PPI and alginate. Following a review by the Health Technology Assessment 
of the National Institute for Health Research, funding was achieved in 2013 to conduct a 
randomised double-blind placebo controlled study to assess the clinical effectiveness of a PPI 
(lansoprazole). The inclusion of an alginate in the study was removed following the funding 
review. The trial was entitled the Trial of Proton Pump Inhibitors in Throat Symptoms, or 
TOPPITS (trial registration numbers: ISRCTN38578686, EudraCT number 2013-004249-17). 
I was involved in the study design from the outset as a co-applicant and have been a Trial 
Management Group (TMG) member since the trial commenced. I have acted as Principal 
Investigator on the trial when I worked in Sunderland, and have recruited patients to the trial 
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since 2015 in Newcastle. In addition to contributing to the trial delivery and TMG oversight, I 
have taken an active role in the subsequent analysis of results. The following description of 
the TOPPITS trial is a summary taken from the published trial protocol [43]. 
 TOPPITS Protocol 
Aim 
This was a non-commercial study to determine the clinical effectiveness of the proton pump 
inhibitor lansoprazole compared with placebo, in patients referred to secondary care with 
persistent throat symptoms. 
 
Inclusion Criteria 
Referred with a persistent (over 6 weeks) primary throat symptom—globus, hoarseness, throat 
clearing, throat discomfort, choking spasms, excess mucus/ postnasal drip or otherwise 
unexplained night-time cough or choking. Score of 10 or more on the non-heartburn items of 
the RSI. 
Outcomes Measures 
Three patient-reported outcome measures were collected, along with a score of the voice box 
appearances, and basic demographic details. The measures were taken at baseline (entry to the 
trial), four months after treatment and 12 months. 
The TOPPITS primary outcome was the change in Reflux Symptom Index (RSI) at four 
months in the treatment and placebo groups in an intention to treat analysis. The nine-item 
RSI total score (0-45) allowed comparison with previous studies. We planned however to 
report also the RSI score omitting the heartburn item (0-40), which we and others noted can 
skew the results in favour of PPI in past small trials. Our proposed analysis would also 
address the issue of severity variation, through our stratification variables of site and baseline 
severity. 
The Comprehensive Reflux Symptom Score (CReSS) is a 34 item questionnaire of 
oesophageal and extra-oesophageal symptoms[44].  It has been tested on groups of “throat” 
patients, healthy controls and those attending for an upper gastrointestinal endoscopy.  It has 
three statistically robust symptom factors: gastrointestinal/oesophageal (14 items), an upper 
airway factor (eight items) – relating to cough, breathing, mucus and hoarseness, and a third, 
obstruction / choking globus factor (pharyngeal factor- seven items)[45]. 
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Quality of life: Change in Laryngopharyngeal Reflux-Health Related Quality of Life (LPR-
HRQL) total score and subscale at four and 12 months. 
Laryngeal mucosal changes – as scored with the Reflux Finding Score (RFS). 
The outcome measures which were used in the TOPPITS trial are shown in the Appendices. 
Subsequent chapters will detail the relevant published data and analyses of previous trials to 
have used the specific outcome. 
Intervention 
The active intervention was a 16-week (four-month) course of a 30mg twice daily dose of the 
proton pump inhibitor lansoprazole. 
Control 
Participants in the control arm received a 16-week (four-month) course of twice daily 
matched placebo capsule. 
 Methods to assess outcomes measures used for throat symptoms 
Section 1.2 has described the TOPPITS trial, from which this thesis data arises, and has set 
out the patient reported outcome measures used and the scoring tool for the throat 
appearances. This section will explore some of the previous research into these outcome 
measures and the statistical analyses used. The chapter will also explore relevant statistical 
analyses that are in use to assess the utility of patient reported outcome measures, in patients 
with persistent throat symptoms and in other similar diseases. 
 Patient reported outcome measures used in “LPR” 
Given the lack of any reproducible investigations to diagnose reflux related throat symptoms, 
or “LPR”, and the lack of correlation between throat appearances and reflux investigations, 
patient reported outcome measures (PROMs) have become the principal method of assessing 
and monitoring throat symptoms[46]. A literature review using Ovid Medline was performed 
using the search terms “patient reported outcome measures” and “laryngopharyngeal reflux”. 
This review intended to highlight the evidence pertaining to the three PROMs and the RFS 
used in TOPPITS, and to review the statistical methods used to analyse the PROMs in this 
setting.  
Reflux Symptom Index 
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Originally validated in 2002, the RSI was assessed in 25 patients with LPR compared to 25 
healthy controls[22]. The mean age of the LPR group was 57. The RSI was completed twice 
prior to LPR treatment to assess test-retest reliability. Results were compared to the 30-item 
Voice Handicap Index. LPR was “diagnosed” using dual-probe 24-hour pH monitoring. 
Patients were treated with 6 months twice daily PPI. Patients were not involved in the 
construction of the questionnaire. The mean RSI in the LPR group was 19.9 (sd. 11.1) and 
20.9 (9.6) in the two pre-treatment tests. There was a mean 8(4) days between visits to 
complete the RSI. Test-retest reliability was r=0.81 using Pearson’s correlation coefficient.  
After 6 months treatment, the mean RSI was 12.8 (10.0). The mean RSI in the control group 
was 11.6 (95% CI 9.7 – 13.6). 
CRESS 
The 34-item questionnaire was originally described in 2009[44] to include the RSI items and 
the Gastro-oesophageal reflux disease (GORD) Symptom Assessment Scale (GSAS). The 
GSAS was identified as an adequate symptom scale when assessed in a systematic review, 
although this review highlighted some deficiencies in all scales and the need for a more 
appropriate tool to use to measure therapies outcomes[47]. There was recognition that the 
RSI, whilst popular, lacked a throat pain symptom, and the traditional GORD symptoms were 
bundled in one poly-symptomatic item. The RSI item covering “heartburn, indigestion, chest 
pain and stomach acid coming up” was unbundled into four individual items. The 15 items 
from the GSAS were added, along with the 10 symptoms that had been originally included 
with the GSAS. These 10 items had been removed largely due to low endorsement via a 
telephone interview; the CReSS authors felt some of these items had been removed despite 
high endorsement and chose to include them all. Items common to both questionnaires were 
included as one. Each item is scored from zero to five. The questionnaire was given to 62 
patients attending the ENT department with chronic throat symptoms, based on the referral 
letter.  
Item endorsement (scores >zero) showed the following symptoms were recorded by over 50% 
of the patients: Throat clearing (RSI item, 79%), pressure / lump in throat (GSAS item, 70%), 
excess mucus (RSI, 66%), feeling things stuck in throat (GSAS item, 62%), back pain (GSAS 
omitted item - 59%), hoarseness (GSAS item, but is also on RSI, 52%), flatulence (GSAS 
item, 52%), mucus dripping down back of throat (RSI in addition to excess mucus, 51%), 
pain in throat (GSAS item, 51%). 
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Correlation of the disaggregated RSI items, within the CReSS questionnaire, was performed 
using Pearson’s correlation coefficient[44]. Each RSI item contained significantly correlated 
disaggregated symptoms, other than pressure in chest which was not correlated with either 
indigestion or heartburn. Heartburn and indigestion were endorsed by 46%, and pressure in 
chest by 26%. Stomach acid coming up was reported by 36%. A cluster analysis was 
performed to assess if defined clusters of symptoms could map to clinical conditions.  
However, no new symptom patterns were identified and the methodology was not explored 
further. Whilst the specific type of cluster analysis used was not specified, the results state a 
dendrogram was evaluated within SPSS. This would suggest that the hierarchical cluster 
analysis methods had been used. 
The 34-item questionnaire was subsequently termed the Comprehensive Reflux Symptom 
Scale (CReSS). It was further evaluated on 639 patients: 103 controls (staff, friends and 
hearing aid clinic attenders), 359 patients attending for oesophagogastroduodenoscopy 
(OGD), and 177 Ent patients referred with throat symptoms[45]. There was a high level of 
positive scoring (>zero) for all items on the CReSS. Interestingly, controls most frequently 
endorsed back pain (43%), headache (31%) and flatulence (26%); OGD patients heartburn 
(76%), indigestion (75%), and stomach acid coming up (72%) – i.e. three of the four 
symptoms in the single RSI item; and the ENT / throat patients throat clearing (80%), 
hoarseness (71%) and pressure / lump (65%). Internal reliability was assessed with 
Cronbach’s α (0.93). A factor analysis using principal components analysis identified 
statistically robust symptom factors: gastrointestinal (oesophageal); an upper airway factor – 
relating to cough, breathing, mucus and hoarseness; and a third, obstruction / choking / globus 
factor (pharyngeal or throat)[45]. Each item is scored on a zero to five Likert scale, giving a 
range of total scores 0-170. There are 17 oesophageal items (score 0 – 85), nine upper airway 
items (score 0 – 45), and five pharyngeal items (score 0 – 25). Three items do not lie within 
the three main groups (score 0-15). 
 
LPR-HRQL 
The Laryngopharyngeal Reflux Health Related Quality of Life Questionnaire (LPR-HRQL) is 
a 43 item self-administered questionnaire[48]. It is composed of four domains (Voice – 12 
items, Cough – six items, Throat Clearing – six items, and Swallow – five items). Each of these 
items is scored on a zero to six Likert scale. The scoring system for the questionnaire is 
described in section 2.2. The reliability, validity and responsiveness of this instrument was 
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assessed in 2005[48]. To date this questionnaire has not been widely used in studies. The 
rationale for its development was the recognition that health related quality of life instruments 
existed for GORD and voice, but not for “LPR”. The instrument was developed from a literature 
review with input from several specialist clinicians.  
The instrument was assessed on 117 patients diagnosed with LPR based on symptoms and 
throat / voice box appearances (RFS), who received twice daily PPIs for six months. 
Symptoms were assessed at two monthly time points including baseline. Patients also 
completed the Short-form 36 (SF-36), the Voice Handicap Index (VHI), the Quality of Life in 
Reflux and Dyspepsia (QOLRAD) and the Overall Treatment Effect (OTE). Statistical, 
construct and concurrent validity were analysed through descriptive statistics, factor analysis 
and relationships with the other questionnaires. Cronbach’s α was used to assess internal 
reliability, and Pearson’s correlation coefficient to assess test-retest reliability. 
Responsiveness was assessed over two time points with a paired t-test. The burden of 
completing the questionnaire was assessed by the ability and time to complete it.  
The results stated good variability on all items with ranges spanning all potential values for 
each item. There were no floor or ceiling effects noted. The scales demonstrated normal 
distributions. All but one domain showed a single factor structure with the voice/ hoarse 
domain having more than one. The variability compared favourably with the VHI and 
QOLRAD. The voice/ hoarse domain correlated substantially (0.88) with the VHI (as would 
be expected, with both tools assessing similar symptoms). Internal consistency ranged from 
0.84 – 0.93, although the swallow domain was lower at 0.69. The test-retest reliability ranged 
from 0.90 to 0.64. The responsiveness analysis suggested a minimum clinically meaningful 
difference of five on each overall domain score, and 10 for the overall impact of acid score. 
The questionnaire was felt to have been completed within 30 minutes. 
 
 
Instrument validation in throat symptoms 
The TOPPITS trial was conceived in 2012 and funded in 2013. The research team recognised 
certain deficiencies in the RSI, as the “market-leading” patient reported outcome measure and 
wished to include further symptom scales in the trial. Since the trial began further validation 
work had been conducted on the CReSS scale, as outlined above. A recent systematic review 
of PROMs relating to “LPR” performed in-depth analysis of each measure’s development and 
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validity[46]. They identified seven relevant PROMs, including the RSI, CReSS (termed the 
LPR-34 in this review) and LPR-HRQL.  They assessed each PROM against a checklist of six 
measurement properties[46] that comprised: conceptual model, content validity, reliability, 
construct validity, interpretability and scoring, burden and presentation.  Unfortunately, 
despite the rigorously conducted review using transparent search criteria, the authors did not 
identify the further work on the CReSS questionnaire in July 2015, despite it having already 
been published in February 2015. As such, the LPR-34 as it was labelled, failed to meet many 
of the desired measurement properties. Had the more recent work been available to the 
authors then the CReSS questionnaire would have compared favourably in terms of reliability 
and construct validity. 
The review does not single out a particular questionnaire as being the most rigorously 
developed. It recommends that over 100 participants be required for optimal factor analysis; 
only the LPR-HRQL of the three measures used in TOPPITS met this criterion on their 
available evidence (the subsequent CReSS analysis on 639 patients would have met this 
criterion). Chapter 4 will explain that the numbers of patients required for factor analysis also 
depends on the number of questionnaire items included; the more items, the more patients 
required.  The RSI was developed on only 25 patients with the clinical condition of interest. 
The population on which the measures were assessed varied. Of course, defining such a 
population, when a definition of the condition does not exist is contentious. There are no 
established investigations that define LPR, hence the rationale to base treatments around 
patients’ symptoms. With this in mind, it was clear that patient involvement in the 
development of measures was very much lacking. The review states that the LPR-HRQL 
engaged patients in its development, but the methods state a focus-group of clinicians were 
involved. Only the RSI and LPR-HRQL measured aspects of response to change, albeit in 
uncontrolled cohorts of patients treated with PPIs. The RSI was not assessed with a factor 
analysis as part of the validating work, however Printza et al[49] and Cathcart et al [50] did so 
in later studies. This work will be explored further in Chapter 4. 
Exploratory factor analysis techniques have been used to analyse PROMs in throat symptoms 
as detailed above. Further details will be specified in Chapter 4 and Chapter 5. Other than the 
original study which set out the 34 –item questionnaire which led to the CReSS, cluster 
analysis has not been explored[44]. Factor analysis is a recognised item reduction technique 
which can then be used to define the variables included in cluster analysis. Adnane et al [51] 
assessed 131 patients undergoing treatment for chronic rhinosinusitis, collecting demographic 
data, objective investigations and a patient reported outcome measure. Three distinct clusters 
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of patients were identified with differing quality of life outcomes after treatment. The 
variables that were included in the cluster modelling were chosen following factor analysis 
that reduced the demographic data, comorbidity, subjective and objective clinical findings 
down to nine factors. A two-step cluster analysis was then performed using SPSS.  
Reviewing the literature pertaining to the statistical analysis of throat symptoms PROMs and 
similar medical conditions has shown that exploratory factor analysis of multiple measures, 
and cluster analysis using the factors generated from factor analysis are recognised 
techniques. These techniques could reduce the large volume of symptom data obtained from 
TOPPITS into a more clinically meaningful group of symptoms. 
 The research question 
At the outset of this thesis I chose to explore in detail the wealth of symptom information that 
the TOPPITS trial would offer. I set out to explore symptoms independent to treatment 
outcomes in the trial. TOPPITS was designed to address the common practice of PPI 
prescriptions for patients with throat symptoms. In the course of writing this thesis the 
TOPPITS results have been analysed and show no evidence of benefit in treating patients with 
PPI over placebo when PROMs were analysed. No trends towards a treatment effect have 
emerged. The one conclusion that readers will take from the trial is that PPIs should not be 
prescribed routinely for these patients. In truth, the trial’s research team did anticipate this 
result given the lack of benefit demonstrated in smaller clinical trials. However, we did not 
perhaps envisage such a conclusive lack of treatment effect. 
The work generated from this thesis has therefore gained greater importance. If acid 
suppression medications are not to be used for these patients, then how should they be 
treated? A greater understanding of the symptoms that patients present with would be very 
useful to explore other aetiologies and management strategies for these patients. The TMG 
has discussed whether subgroup analysis of the TOPPITS data would be legitimate. Defining 
subgroups based on an improved understanding of symptoms would be a pre-requisite to even 
consider such a secondary analysis. 
Specific throat symptoms have often been investigated as single entities with research 
addressing globus, catarrh, post-nasal drip, dysphonia and cough alone. The concept of LPR 
has brought all these terms together, often through the patient reported outcome measures 
used in this condition. I believe there is significant overlap amongst the individual symptoms. 
Figure 1-1 shows a diagram I devised for a medically unexplained symptoms conference in 
2013. The diagram’s message was purely based on experience and anecdote, at the time. 
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TOPPITS gives the opportunity to look in detail at symptom reporting by patients and to 
assess how individual symptoms may relate. In light of the TOPPITS results, a greater 
understanding of symptom reporting is required to generate further, much need research into 
appropriate therapies for patients with persistent throat symptoms. 
Much has been written on the signs that may be related to reflux within the throat. The 
literature was summarised in an evidence based conference and subsequently published, 
highlighting the lack of evidence regarding throat signs, attributed to reflux, and citing the 
need for quality research in this area[52]. The most commonly cited study suggesting an 
association between symptoms and signs was conducted on only 40 patients and showed a 
Spearman’s rank correlation of 0.86. TOPPITS will give far greater scope for assessing any 
relationship that may exist between throat symptoms and signs. 
Figure 1-1 The potential overlapping of throat symptoms 
 
 Thesis Aims and Objectives 
 Principal aim 
To explore persistent throat symptoms and signs, in order to identify patterns of specific 








1. To comment on the generalisability of the TOPPITS population, to general throat 
symptom populations, using descriptive analyses for the baseline demographic data, 
patient reported outcome measures (PROMs) and clinician rated throat appearances 
for patients. 
2. Assess the relationship between the different PROMs and clinician rated throat 
appearances with one another. 
3. Attempt to devise a clinically useful classification system for persistent throat 
symptoms, achieved using: 
Exploratory factor analysis of a) the three questionnaires’ individual items combined 
together, and b) the individual questionnaires. 
Relevant cluster analysis techniques.  
 Thesis Layout 
Four chapters will set out the work performed to address each objective: 
Chapter 2 Baseline Demographic Data 
Chapter 3 Relation between outcome measures 
Chapter 4 Exploratory Factor Analysis 
Chapter 5 Cluster Analysis 
Each chapter will comprise an introduction, methods, results, discussion and conclusions.  
Chapter 6 will present the overall thesis conclusions.  





Chapter 2 Baseline Demographic Data 
 Introduction 
The objective for Chapter 2 is to present descriptive analyses for the baseline demographic 
data, patient reported outcome measures (PROMs) and clinician rated throat appearances for 
patients recruited to the TOPPITS trial, and comment on the generalisability of the TOPPITS 
population to general ENT practice. 
 Methods 
 TOPPITS Data management 
The proposed thesis was discussed within the TOPPITS trial management group (TMG). 
Initially, the work in this thesis was planned to fall under the remit of one of the trial’s 
prespecified objectives, detailed within the trial’s Statistical Analysis Plan (SAP). However, it 
was felt that this arrangement would limit the thesis objectives and that greater scope for 
exploring the rich baseline dataset would be achieved with a stand-alone study. A 
proportionate review application was therefore submitted to the research and ethics 
committee, with a favourable response obtained in May 2018 (Appendices - Research Ethics 
Committee Approval).  
The TOPPITS baseline dataset was transferred into SPSS (Statistical Package for the Social 
Sciences) format by the data manager for the clinical trial (Ruth Wood). All patient 
identifiable information was removed other than the unique trial identification number. 
The analysis set included all patients recruited into the TOPPITS trial. As this is baseline data 
only, protocol violation did not affect the data set. There was no requirement to perform an 
intention to treat analysis. Patients who were found to be ineligible post-randomisation and 
protocol violators were retained in the analysis for this thesis.  
The data set included the patient unique trial identification number. It did not contain the 
randomisation group. Variables included in the data set were: 
• Age at recruitment into the trial 
• Gender 
• Body mass index 
• Smoking status 
• Baseline Reflux Symptom Index (RSI) – individual item scores and total score 
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• Baseline Comprehensive Reflux Symptom Score (CReSS) - individual item scores and 
total score 
• Baseline Laryngopharyngeal Reflux – Health related Quality of Life score (LPR-
HRQL) - individual item scores and total score 
• Baseline Reflux Finding Score (RFS) - individual item scores and total score 
 Descriptive Analyses 
All analyses were performed using SPSS version 24.  
Demographics 
Descriptive statistics for age and body mass index (BMI) include the mean, standard 
deviation, median, interquartile range and range. Age and BMI are displayed graphically 
using histograms. Gender and smoking status are described using as frequencies and 
percentages. 
Reflux Symptom Index 
The Reflux Symptom Index (RSI)[53] is a nine-item self-administered questionnaire (see 
Appendices - The Reflux Symptom Index). Each item is scored on a Likert scale zero to five, 
giving a total score range of 0-45. Higher scores represent increasing severity of patient reported 
symptoms. There are suggestions that the “heartburn” item may influence much of the variation 
in scores of the RSI in previous studies. The RSI was also analysed without the heartburn item; 
termed RSI-HB, with a range of 0-40.  
Descriptive statistics for both the RSI and the RSI-HB include the mean, standard deviation, 
median, inter-quartile range, and range for the total scores. The mean total score for the RSI is 
reported. However, for each item on the questionnaires (given the construct of each item), the 
median score and range are recorded in addition to the mean. The data was assessed for 
normality. The RSI and RSI-HB are represented graphically (histograms and normal curves). 
Individual items from the RSI are ranked according to median scores.  
Data were assessed for normality using graphical methods. An approximate rule to assess 
normality is to consider the Kurtosis and Skewness scores of the data, with a Kurtosis value 
between -3 and +3 and a Skewness value between -0.8 and +0.8 suggesting normality. 
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Comprehensive Reflux Symptom Score 
The Comprehensive Reflux Symptom Score (CReSS) [54] is a 34 item self-administered 
questionnaire of oesophageal and extra-oesophageal symptoms which has been tested on groups 
of “throat” patients, healthy controls and those attending for an upper gastrointestinal 
endoscopy (see Appendices - The Comprehensive Reflux Finding Score).  Each item is scored 
on a zero to five Likert scale, giving a range of total scores 0-170. Descriptive statistics for the 
total score include the mean, standard deviation, median, inter-quartile range, and range. For 
individual factors the scores are presented as median and ranges. Means and standard deviations 
were derived for each item on the questionnaire and ranked. The data are also presented 
graphically. 
Laryngopharyngeal Reflux Health Related Quality of Life Questionnaire 
The Laryngopharyngeal Reflux Health Related Quality of Life questionnaire (LPR-HRQL) is 
a 43 item self-administered questionnaire[48] (Appendices - The Laryngopharyngeal Reflux 
Health Related Quality of Life Questionnaire). It is composed of four domains (Voice – 12 
items, Cough – six items, Throat Clearing – six items, and Swallow – five items). Each of these 
items is scored on a zero to six Likert scale. The total for each domain is scored by taking the 
total score, subtracting the mean and dividing by the standard deviation – to give the z-score 
for each domain. Following each set of domain questions there is a “thermometer” question for 
that domain, scored 1 – 10. The last 10 questions cover the domain “overall impact of acid-
reflux” and are scored 1-10.  An “overall score” is calculated by adding the four thermometer 
scores to the 10 overall impact of acid reflux questions, to give a score of 14 – 140. The scoring 
instructions state that missing data can be imputed if less than six items are missing from the 
voice domain, or less than 3 for the cough, throat and swallow domains.  
Descriptive statistics for the domain scores, thermometer scores and “overall impact of acid 
reflux” include the mean, standard deviation, median, inter-quartile range, and range. Medians 
and ranges were derived for each item on the questionnaire. The data are also presented 
graphically. The domain thermometer scores were ranked.  
Reflux Finding Score 
The Reflux Finding Score (RFS)[23] is a clinician assessed rating of the appearance of the 
larynx (Appendices - The Reflux Finding Score). There are eight items, with each item scored 
using varying categories. Some items score: zero = absent (clinical finding), two =present. 
Some items score: zero =none, two=mild, three=severe, four=obstructive. The total score range 
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is between 0-29. Descriptive statistics include the median, inter-quartile range, and range. 
Absent/present items were described according to frequencies and percentages. These are also 
assessed graphically.  
 Results 
The TOPPITS baseline dataset contained data on 344 individual patients, recruited over 8 
centres in the UK. Institutional recruitment was as follows: Newcastle – 132 (38%), 
Nottingham – 70 (20%), Sunderland – 46 (13%), Glasgow – 39 (11%), Manchester – 27 
(7.8%), Stockport – 11 (3.2%), Birmingham – 10 (2.9%), Brighton – 9 (2.6%).  
Initial data screening revealed five patients with duplicate identification numbers and no 
demographic or questionnaire data. These were removed. Three patients were randomised to 
the TOPPITS trial but subsequently were found to be ineligible to continue in the trial. 
Baseline data existed for two of these patients and has been included in this thesis analysis. 
Data is present on 344 patients for this baseline analysis. 
There was no missing data for patients’ age or gender. Data was missing on Body Mass Index 
for five patients and on smoking status for five patients. Patients with missing data for these 
demographics were excluded from the descriptive statistical analysis. 
 Patient Demographics 
Over half of the population were female (195, 56.7% - 149 males, 43.3%) with mean age 52.1 
years (sd 13.7, Table 2-1). The ages were normally distributed (Figure 2-1 shows low 
Kurtosis and Skewness values; Kurtosis -0.59. Skewness -0.20). The mean BMI was 28.1 
(Figure 2-1) with missing data for five patients.  The BMI scores were not normally 
distributed, given a Kurtosis score outside of an acceptable range of -3 to +3, and a Skewness 
score outside an acceptable range of -0.8 to +0.8 (Figure 2-2- Kurtosis 3.28 . Skewness 1.28).  
Figure 2-1 also shows a box and whisker plot of the BMI scores. The box depicts the mean 
and interquartile range with the whiskers showing the range, with separate outlying scores. 
There were two particular outliers with BMIs of 11.3 and 56.9. It is possible that these were 
errors in the data collection at source, given how extreme the two values are. With these two 
outliers removed the BMI distribution is positively skewed, as expected if compared to the 
general UK population (Kurtosis = 1.83. Skewness = 0.97 – which remains greater than 0.8). 
There were 100 patients who were smokers (29.5%) with missing data for 5 patients. 
Amongst smokers, , with a median cigarette consumption was 10 pack years, with the 
distribution of pack years smoked being positively skewed (Table 2-1 and Figure 2-1). 
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Table 2-1 Baseline distribution of demographics 
Demographic (n= ) Mean SD Median IQR Range 
Age (344) 52.1 13.7 53 20 (43 – 63) 20 – 84 
BMI (339) 28.1 5.62 27.1 6.05 (24.5 – 
30.6) 
11.3 – 56.9 
“Pack years smoked” 
if current smoker 
(100) 




Figure 2-1 Graphical representations of Age and BMI distributions 
Histogram showing age distribution with 
overlying normal curve 
Histogram showing BMI distribution 
with overlying normal curve 
  
Box and whisker plot of BMI distribution Histogram showing distribution of "pack 





 Questionnaire Data 
2.3.2.1 Reflux Symptom Index (RSI) 
The total score RSI data was missing for two patients; both with single items missing from 
their questionnaires.  The mean total RSI score was 21.9 (sd. 7.2, Table 2-2) and was 
normally distributed (Figure 2-5). Table 2-3 and Table 2-4 show the scores for the individual 
RSI item scores. The items “sensation of something caught in the throat or lump in the throat” 
and “throat clearing” had the highest population mean and median. “Difficulty swallowing 
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food, liquids or tablets” and “ breathing difficulties or choking episodes” had the lowest 
population mean scores. Figure 2-3 shows the graphical representation of the RSI items 
ranked according to population mean and median scores. Graphically, the individual RSI item 
scores were not normally distributed (Shown in the appendix Figure 7-1, Figure 7-2, Figure 
7-3, Figure 7-5, Figure 7-6, Figure 7-7, Figure 7-8, Figure 7-9). 
Table 2-2 Distribution of Total RSI scores 
n= 342 
Mean 21.9 
Standard deviation 7.20 
Median 21 
Interquartile range 11 (16 – 27) 
Range 10 – 43 
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Figure 2-2 Histogram showing distribution of Total RSI score with overlying normal 
curve 
 
Kurtosis = -0.33. Skewness = 0.43 
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Table 2-3 Distribution of individual RSI items 






1  Hoarseness 2.39 1.62 3 3 (1 – 4) 0 - 5 
2  Throat clearing 3.44 1.29 4 1 (3 – 4) 0 – 5 
3  Excess throat mucus 2.85 1.56 3 2 (2 – 4) 0 - 5 
4  Difficulty swallowing 1.68 1.61 2 3 (0 – 3) 0 – 5 
5  Coughing lying down 2.12 1.64 2 3 (0 – 3) 0 – 5 
6  Breathing difficulties 1.58 1.62 1 3 (0 – 3) 0 – 5 
7  Troublesome cough 2.49 1.71 3 3 (1 – 4) 0 – 5 
8  Lump in throat 3.51 1.44 4 2 (3 – 5) 0 – 5 
9  Heartburn 1.79 1.60 1.5 3 (0 – 3) 0 – 5 
 
Table 2-4 RSI items ordered by rank mean score 
Rank mean score RSI item Mean score 
1 8  Lump in throat 3.51 
2 2  Throat clearing 3.44 
3 3  Excess throat mucus 2.85 
4 7  Troublesome cough 2.49 
5 1  Hoarseness 2.39 
6 5  Coughing lying down 2.12 
7 9  Heartburn 1.79 
8 4  Difficulty swallowing 1.68 
9 6  Breathing difficulties 1.58 
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Figure 2-3 Bar chart showing ranked mean and median RSI item scores 
 
Reflux Symptom Index minus Heartburn score (RSI-HB) 
With the ninth RSI item omitted, the mean RSI –HB score was 20.1 (Table 2-5). The 
distribution of the RSI-HB scores appeared normal (Figure 2-4). 
Table 2-5 Distribution of Total RSI-HB scores 
n= 342 
Mean 20.1 
Standard deviation 6.65 
Median 19 
Interquartile range 9 (15 – 24) 














Figure 2-4 Histogram showing distribution of Total RSI-HB scores with overlying 
normal curve 
 
Kurtosis = -0.37. Skewness = 0.49 
 
2.3.2.2 Comprehensive Reflux Symptom Score 
Data was missing for nine patients: five with no CReSS submitted and four with several 
missing items. These nine patients were removed from the analysis. 
The mean total score CReSS score was 51.2 (s.d. 27.2, Table 2-6). The total CReSS score 
appeared normally distributed, with Kurtosis and Skewness scores within an acceptable range 
(Figure 2-5). Table 2-7 and Table 2-8 show the descriptive data and ranking of the individual 
CReSS items. The highest ranked items were “throat clearing”, “feeling things stuck in 
throat” and “lump in throat”. The lowest ranked items were “vomiting”, “hiccups” and 
“decreased appetite”. 
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Table 2-6 Distribution of Total CReSS scores 
n= 335 
Mean 51.2 
Standard deviation 27.2 
Median 49 
Interquartile range 39 (30 - 69) 
Range 2 - 142 
 
Figure 2-5 Histogram showing distribution of Total CReSS score with overlying normal 
curve 
 
Kurtosis = 0.27. Skewness = 0.71 
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Table 2-7 Descriptive data for the individual CReSS items scores 




1  Heartburn 1.36 1.46 1 2 (0 – 2) 0 – 5 
2  Pressure in chest 1.09 1.42 0 2 (0 – 2) 0 – 5 
3  Regurgitation 1.12 1.36 1 2 (0 – 2) 0 – 5 
4  Acid/sour taste in mouth 1.50 1.48 1 3 (0 – 3) 0 – 5 
5  Gurgling stomach 1.69 1.56 1 3 (0 – 3) 0 – 5 
6  Lump in throat 2.86 1.74 3 3 (1 – 4) 0 – 5 
7  Difficulty swallowing food 1.44 1.61 1 3 (0 – 3) 0 – 5 
8  Difficulty swallowing liquids 0.83 1.23 0 1 (0 – 1) 0 – 5 
9  Nausea 0.91 1.38 0 2 (0 – 2) 0 – 5 
10  Pain in throat 1.49 1.60 1 3 (0 – 3) 0 – 5 
11  Vomiting 0.42 0.99 0 0 (0 – 0) 0 – 5 
12  Bloating 1.36 1.63 1 2 (0 – 2) 0 – 5 
13  Belching 1.42 1.57 1 3 (0 – 3) 0 – 5 
14  Flatulence 1.52 1.57 1 3 (0 – 3) 0 – 5 
15  Hiccups 0.62 1.07 0 1 (0 – 1) 0 – 5 
16  Decreased appetite 0.73 1.28 0 1 (0 – 1) 0 – 5 
17  Rush of saliva in mouth 1.20 1.47 1 2 (0 – 2) 0 – 5 
18  Feeling full early 1.14 1.49 0 2 (0 – 2) 0 – 5 
19  Bad breath 1.05 1.41 0 2 (0 – 2) 0 – 5 
20  Back pain 1.92 1.74 2 3 (0 – 3) 0 – 5 
21  Headache 1.38 1.47 1 2 (0 – 2) 0 – 5 
22  Choking 1.14 1.53 0 2 (0 – 2) 0 – 5 
23  Coughing upright 1.99 1.61 2 3 (0 – 3) 0 – 5 
24  Coughing after eating 1.49 1.56 1 3 (0 – 3) 0 – 5 
25  Coughing lying down 1.95 1.73 2 3 (0 – 3) 0 – 5 
26  Wheezing 1.07 1.52 0 2 (0 – 2) 0 – 5 
27  Difficulty breathing 1.10 1.57 0 2 (0 – 2) 0 – 5 
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28  Hoarseness 2.08 1.76 2 4 (0 – 4) 0 – 5 
29  Throat clearing 3.20 1.50 4 2 (2 – 4) 0 – 5 
30  Excess mucus 2.41 1.82 2 3 (1 – 4) 0 – 5 
31  Mucus dripping in throat 2.06 1.89 2 4 (0 – 4) 0 – 5 
32  Feeling things stuck in throat 2.89 1.79 3 3 (1 – 4) 0 – 5 
33  Indigestion 1.30 1.45 1 2 (0 – 2) 0 – 5 
34  Stomach acid coming up 1.41 1.55 1 3 (0 – 3) 0 – 5 
 
Table 2-8 CReSS items ordered by rank mean score 
Rank mean score CReSS Item Mean Score 
1 29  Throat clearing 3.20 
2 32  Feeling things stuck in throat 2.89 
3 6  Lump in throat 2.86 
4 30  Excess mucus 2.41 
5 28  Hoarseness 2.08 
6 31  Mucus dripping in throat 2..06 
7 23  Coughing upright 1.99 
8 25  Coughing lying down 1.95 
9 20  Back pain 1.92 
10 5  Gurgling stomach 1.69 
11 14  Flatulence 1.52 
12 4  Acid/sour taste in mouth 1.50 
13 10  Pain in throat 1.49 
14 24  Coughing after earing 1.49 
15 7  Difficulty swallowing food 1.44 
16 13  Belching 1.42 
17 34  Stomach acid coming up 1.41 
18 21  Headache 1.38 
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Rank mean score CReSS Item Mean Score 
19 1  Heartburn 1.36 
20 12  Bloating 1.36 
21 33  Indigestion 1.30 
22 17  Rush of saliva in mouth 1.20 
23 18  Feeling full early 1.14 
24 22  Choking 1.14 
25 3  Regurgitation 1.12 
26 27  Difficulty breathing 1.10 
27 2  Pressure in chest 1.09 
28 26  Wheezing 1.07 
29 19  Bad breath 1.05 
30 9  Nausea 0.91 
31 8  Difficulty swallowing liquids 0.83 
32 16  Decreased appetite 0.73 
33 15  Hiccups 0.62 
34 11  Vomiting 0.42 
 
2.3.2.3 Laryngopharyngeal Health-Related Quality of Life (LPR-HRQL) 
There was missing data for 10 patients from the Voice domain, 12 patients from the Cough 
domain, 10 patients from the Throat domain, and six patients from the Swallow domain. 
Following imputation of missing individual items across the domains, according to the pre-
defined methodology, there was missing data for six patients from each of the four domains. 
These patients have been removed from the analysis. 
Table 2-9, Table 2-10 and Table 2-11 show the descriptive data for the domain scores, 
thermometer scores and “overall impact of acid” scores within the LPR-HRQL. Given the 
varying number of items within the domains, Table 2-9 gives a mean score per item for each 
domain. This shows that the throat clearing domain had the highest mean score per item, with 
voice the lowest score. 
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Table 2-9 Descriptive data for the domain scores in the LPR-HRQL 







Voice 338 14.9 15.2 8 14 (6 – 20) 0 – 67 1.24 4 
Cough 338 8.56 9.06 5 13.25 (0.75 – 
13) 
0 – 35 1.43 2 
Throat 
clearing 
338 9.27 7.38 8 11 (3 – 14) 0 – 35 1.55 1 
Swallow 338 7.12 6.69 5 9 (2 – 11) 0 - 30 1.42 3 
 
Table 2-10 Descriptive data for the thermometer scores in the LPR-HRQL 
Domain n =  Mean SD Median Interquartile 
range 
Range Rank 
Voice 338 3.33 2.81 2 4 (1 – 5) 0 – 10 4 
Cough 338 3.54 2.68 3 4 (1 – 5) 0 – 10 3 
Throat 
clearing 
338 4.18 2.67 4 4 (2 – 6) 0 – 10 2 




Table 2-11 Descriptive data for the overall score for the LPR-HRQL 
n = 338 
Mean 50.8 
Standard deviation 28.0 
Median 46 
Interquartile range 44 (26 – 70) 
Range 14 - 134 
 
 Reflux Finding Score (RFS) 
There was missing data for 90 patients. RFS scores were not obtained for these patients. 
Explanations for this missing data are covered in the discussion. Table 2-12, Table 2-13 and 
Figure 2-6 show the descriptive data and distribution of the total RFS scores and individual 
RFS items. The mean score was 8.78 (s.d. 4.14). Given the variable scoring range for the 
individual RFS items, no one item was particularly higher than the others. Whilst the 
erythema score was the highest mean score, this item had a larger standard deviation and 
interquartile range than posterior commissure oedema. 
Table 2-12 Descriptive data for the Total RFS scores 
n =  254 
Mean 8.78 
Standard deviation 4.14 
Median 9 
Interquartile range 5 (6 – 11) 
Range 0 - 24 
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Table 2-13 Descriptive data for the individual RFS item scores 
RFS Item (maximum 
score) 
Mean SD Median Interquartile 
range 
Mode 
Subglottic oedema (2) 0.86 0.99 0 2 (0 – 2) 0 
Ventricular obliteration 
(4) 
1.48 1.25 2 2 (0 – 2) 2 
Erythema (4) 2.07 1.51 2 4 (0 – 4) 2 
Vocal fold oedema (4) 0.79 1.00 0 2 (0 – 2) 2 
Diffuse laryngeal oedema 
(4) 
1.39 0.99 2 2 (0 – 2) 2 
Posterior commissure 
oedema (4) 
1.91 0.90 2 2 (1 – 3)  2 
Granuloma (2) 0.05 0.31 0 0 0 
Thick mucus (2) 0.21 0.62 0 0 0 





















In common with many other reported studies assessing throat symptoms, there were more 
females (57%) than males initially recruited to the TOPPITS trial. A case series of 1044 
patients with similar symptoms had an identical proportion of females[28]. Within the 
TOPPITS population, the mean age of 52 and BMI of 28 are very similar to those found in 
other interventional trials of throat symptom management[55]. 
 RSI comparison with published data 
The RSI was chosen as the primary outcome measure in the TOPPITS trial on the basis of its 
popularity in the published literature, allowing comparisons to be made and allowing the 
trial’s results to be reflected into common practice. The RSI mean was 21.9 (sd 7.2). 
Accepting that the minimum score in the sample has to be 10, given the eligibility criteria for 
TOPPITS, graphically and with low kurtosis and skewness scores, the data can be considered 
normally distributed. The original study that described the RSI on 25 symptomatic patients 
found the RSI to be 20.9 (9.6) in one of the baseline measurements. The largest case series 
published quote a mean pre-treatment RSI values of 15.1 in a series of 455 patients [27] and 
13.8 in a series of 1044 patients[28]. Lee et al [27] do not quote a standard deviation for the 
entire group, but do so for the individual RSI items and also for subgroups. For example the 
RSI for patients aged between 30 and 40 was 16.2 (sd 8.1). These figures are lower than the 
baseline values for the RSI in the TOPPITS population, but the cited publications are from all 
comers presenting to a specialist clinic, and not those patients eligible for a clinical trial. In 
comparison with other interventional trials, Reichel et al[56] recruited 62 patients with an RSI 
>13 (TOPPITS stated RSI without the heartburn item >10); the mean RSI in the group 
receiving PPI was 23.1 (sd 7.5) and in the control group 21.8 (sd 6.7). McGlashan et al 
recruited 49 patients with an RSI > 10 to a randomised controlled study assessing a liquid 
alginate; the RSI in the treatment group was 23.9 (sd 7.0) and in the control group 24.6 (7.4). 
In a recent non-randomised study of the effects of alginate in addition to PPI in 72 
respondents, the RSI was 19.2 (sd 7.4 – calculated using the published confidence intervals) 
in the alginate group and 21.3 (9.0) in the alginate and PPI group. Whilst the mean RSI in the 
published populations varies, with lower scores in non-selected case series and higher scores 
in trials with entry criteria, an interesting finding throughout is the similarity in standard 
deviation between trials. 
During the design phase of the TOPPITS trial, the research team were concerned that PPI 
treatment would produce significant improvements in the traditional heartburn symptom, over 
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placebo. During the evidence based medicine conference in 2011, this concern was discussed 
and many clinicians were sceptical that the improvements in the RSI scores in case series of 
patients treated with PPIs may have been largely due to improvements in heartburn, for which 
PPIs are effective. For this reason the eligibility criteria for TOPPITS was based on a 
symptom score omitting the RSI heartburn item. The results presented  by Reichel et al[56] 
would support this concern over preferential heartburn improvements with PPI. Whilst they 
concluded that symptoms improved in 30 patients receiving PPI compared to 28 receiving 
placebo, as measured by a change in total RSI, the only single symptom that was significantly 
different between the two groups was the heartburn item of the RSI. 
Selecting patients on the basis of the RSI without the heartburn item for entry into the 
TOPPITS trial could have resulted in a trial with less patients with traditional heartburn as 
their principle symptom than would otherwise normally be seen in clinics. Ranking the RSI 
individual items has shown that the heartburn item was the seventh highest score. Figure 2-7 
shows the RSI items ranked, from the largest published series of 1044 patients[28]. The 
heartburn item was ranked fifth. 
 
Figure 2-7 Histogram to show ranked RSI items from Haberman et al. 
 
Lee et al similarly found that the heartburn item was ranked fifth on the RSI[27].  The highest 
scored items in the TOPPITS baseline data are consistent with those from the two 
comparative large series; a feeling of a lump in the throat, throat clearing and excess mucus. 
The comparative studies may have found the heartburn item slightly higher ranked than in 











TOPPITS would therefore appear generalisable and representative of patients presenting to 
standard ENT clinics. 
The clinical relationship between heartburn and persistent throat symptoms is a matter of 
debate and requires further research to define it. Whilst it is argued that LPR and GORD are 
separate entities, clinicians must appreciate that traditional GORD, or heartburn symptoms are 
prevalent in up to a fifth of the general population. One-fifth of patients presenting with 
persistent throat symptoms may therefore report co-existing GORD symptoms.  
 CReSS comparison with published data 
There are no other interventional trials that have reported on CReSS outcomes. Drinnan et 
al[45] evaluated the CReSS with 639 patients surveyed. The mean total CReSS score for 177 
patients presenting to ENT with persistent throat symptoms was 32.3 (sd 21.8), for 136 
patients undergoing gastroenterology delivered endoscopy for proven oesophagitis the total 
score was 44.2 (26.9), for 223 patients undergoing endoscopy for non-oesophagitis the total 
score was 39.6 (28.7), and for 100 controls the total score was 6.1 (7.5). The ENT group had 
the highest percentage of positive responders to throat clearing (80%), hoarse voice, lump and 
excess mucus. The oesophagitis group had the highest percentage with heartburn (82%) and 
indigestion. Those undergoing oesophagogastroduodenoscopy without oesophagitis had 
slightly lower scores than those patients with oesophagitis, but the heartburn (72%) and 
indigestion items remained the highest reported in this patient group. 
The mean total CReSS score in the baseline TOPPITS data was 51.2 (27.2); higher than any 
of the groups reported by Drinnin et al. This may reflect the entry criteria into TOPPITs, 
selecting patients with higher symptom reporting. 
 LPR-HRQL comparison with published data 
This appears a complex questionnaire, not necessarily for patients to complete, but in terms of 
the appropriate method to analyse the results. The LPR-HRQL has not been readily adopted. 
Its validity was thoroughly assessed when reported by 117 patients receiving PPIs for “LPR”; 
Carrau at el reported the domain scores of voice, cough, throat and swallow along with the 
overall impact of acid score[57]. No mention is made of how to report the thermometer scores 
that accompany each domain section. Andersson et al reported on the use of the LPR-HRQL 
in validating a Swedish Pharyngeal Reflux Symptom Questionnaire, but no values were 
published for the LPR-HRQL specifically[58]. Vaezi et al[55] did report the total LPR-HRQL 
scores in 145 patients enrolled in an RCT to assess PPI effectiveness. Unfortunately, it is not 
clear from the methods which score they presented; whether it was a score of 140 or whether 
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they had converted it into a score out of 100. The baseline scores were: mean (sd) for the 
treatment group 30.9 (20.6), and for the placebo group 27.9 (19.3). Lee et al do reported the 
LPR HRQL outcomes in 180 patients treated with PPIs[59] with a mean RSI of 13.2 (sd 8.7). 
Similar to Carrau et al, the domain scores and overall acid scores are presented. The total 
score and the thermometer scores were not reported. Table 2-14 shows how the TOPPITS 
scores compare to the two published series. 
Table 2-14 Comparison with published LPR-HRQL domains 
LPR-HRQL domain Carrau et al[57] 
mean (SD) 




Voice 19.7 (16.1) 18.7 (20.7) 14.9 (15.2) 
Cough 7.6 (8.8) 8.8 (10.5) 8.6 (9.1) 
Clear Throat 9.6 (7.6) 7.4(8.7) 9.3 (7.4) 
Swallow 7.6 (5.8) 7.3 (7.3) 7.1 (6.7) 
Overall impact of 
acid 
32.1 (20.9) 23.7 (17.5) 50.8 (28.0) 
 
The individual domains of the questionnaire are problematic to compare as the voice domain 
has 12 items, the cough domain 6, throat 6 and swallow 5. Given the differing number of 
items in the domains, this analysis calculated the mean score per item within each domain. 
The throat clearing domain had the highest score, which would be in keeping with the 
symptoms ranked highest in the RSI and CReSS. However, when the thermometer scores 
were ranked, the swallow domain was ranked first with the throat thermometer score ranked 
as third. A lack of concordance between mean domain item scores and the domain 
thermometer scores does raise the question as to whether the summary thermometer score 
truly represents the domain items. Interestingly, the TOPPITs population appears to have a 
higher overall impact of acid, compared to the other two studies, despite similar scores in the 
other domains. The domain questions ask specific symptom questions. The domain 
thermometers and the overall impact of acid questions ask how particular symptoms affect 
“quality of life”. For Chapter 4 and Chapter 5, only the 4 domains items and scores will be 
used in the exploratory factor analysis and cluster analysis.  
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RFS 
The mean RFS score for the baseline TOPPITS data was 8.78 (sd 4.1). Interestingly this is 
lower than the group of 220 patients who were included in the final TOPPITS primary 
outcome analysis. When the patients who had completed the primary outcome measure within 
the specified window were included, the baseline RFS for this group was 9.4 (3.9).  
Even with the use of a specified scoring tool, assessing the appearance of the throat in a 
standardised manner is demanding. The quality of the endoscope used or the printed / saved 
image will affect appearances. Subjectivity and reporter bias are clearly problems. TOPPITs 
used digital images saved as high-quality data files. These were then analysed by an 
independent clinician, who had no access to the patients’ symptom scores. There was a 
significant volume of missing data for the RFS. When discussed in the TOPPITS trial 
management group, the data tended to be missing for whole groups and time periods of 
recruited patients. Hence, the missing data appeared to be a problem with capturing, storing 
and transferring the images from recruiting centres rather than there being any suggestion of 
selection bias. 
The published RFS scores do vary. Haberman et al quoted a mean RFS of 15.8 in 1044 
patients with a mean RSI of 13.8[28]. This seems a particularly high RFS given the patient 
reported symptoms on the RSI were a lot lower than in the TOPPITS population. Lee et al 
stated the mean RFS to be 9.1 in 455 patients with a mean RSI of 15.1[27]. Interventional 
trials with a minimum RFS entry criteria quote up to 14.9 (sd 2.5) and 10.4 (3.6) [32, 56]. 
Figure 2-6 shows that if the scoring system for each RFS item is taken into account, no single 
item stands out in the TOPPITS baseline population as being particularly frequently reported. 
Granuloma formation and thick mucus appear infrequently reported which would be 
consistent with the author’s experience. Granuloma formation is a particular laryngeal 
finding, often associated with pain. They are so infrequently found that demonstrating any 
causal effect by reflux, a commonly held theory, would seem impossible to achieve. 
As no individual item stands out on the RFS, it would appear sensible to report the RFS as a 





The patient demographics and outcome measures scores from the TOPPITs baseline data are 
comparable to the published literature. The highest scored symptoms were those of a lump in 
the throat, throat clearing and excess throat mucus. Traditional heartburn symptoms were not 
ranked highly and this finding is again in keeping with the published literature. The baseline 
TOPPITS data would therefore appear generalisable and the results from the subsequent 





Chapter 3 Relation between outcome measures 
 Introduction 
Thus far, the thesis has demonstrated that the baseline profile of patients recruited to the 
TOPPITS trial is comparable to similar published interventional trials, in terms of 
demographics, symptoms and throat appearances. TOPPITS offers the unique opportunity to 
assess how three patient reported outcome measures compare and to assess whether the 
symptom reporting relates to throat appearances. 
TOPPITS collected patient reported symptoms using three questionnaires: the RSI, the 
CReSS, and the LPR HRQL. The background to the questionnaires is detailed in Chapter 1. 
The RSI appeared the most popular symptom tool in terms of its frequency of use in 
published studies, but the TOPPITS research team had reservations regarding the ninth 
polysymptomatic item of heartburn, indigestion, chest pain and acid coming up. The CReSS 
was included as an expanded 34 item questionnaire, covering all the RSI items but in 
individual questions. Whilst not a specific objective of TOPPITS, both the RSI and CReSS 
were completed by patients to allow future analysis and assess if one is superior in 
applicability. The LPR-HRQL was used in TOPPITS as it seemingly offered unique quality of 
life data. Whilst it would be expected that three questionnaires assessing the same types of 
symptoms should be positively related in scoring profiles, this is the first study to formally 
assess the relationship between these outcome measures. 
The relationship between persistent throat symptoms and throat appearances is under debate. 
If the described entity of “LPR” truly exists, and it is accepted that the diagnosis of such a 
condition should rely on symptoms, signs and objective testing, then a relationship should be 
demonstrable between these factors. Interventional trials have set inclusion criteria based on 
minimum presenting symptom scores (RSI) and signs (RFS), implying a perceived 
relationship[32, 56]. Given the large number of observational cohort studies reporting the RSI 
and the RFS it is quite interesting to see how few have analysed the relationship between the 
two measures. The single frequently reported study was performed by Mesallam et al[26]. 
Forty randomly selected voice clinic attendees were retrospectively analysed with their 
presenting RSI and recorded laryngeal endoscopy images. Six clinicians, which reduced to 
four (one removed due to poor inter-rater reliability – which could be viewed as unacceptably 
altering the set methodology, and one removed as they could not complete the second 
evaluation), scored the RFS to assess inter-rater reliability (the kappa statistic ranged between 
+0.59 and 0.79). The RSI mean was 20.2 (sd 4.6) and the RFS mean 9.3 (4.4); comparable 
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with the TOPPITS baseline data. The Spearman’s rank coefficient of correlation between the 
RSI and RFS was r= 0.86 (p< 0.0001). 
Age may impact on symptom reporting. Lechien et al found that the baseline RSI was lower 
in older patients, within a cohort of 80 patients treated with PPIs and divided into three age 
groups [60]. However, their age did not appear to affect their reported response to therapy. 
Lee et al also showed that presenting RSI scores reduced with increasing age[27]. 
Body Mass Index would intuitively appear related to reflux.  Jacobson et al demonstrated a 
dose dependent relationship between increasing BMI and frequent reflux symptoms, among 
10,545 women [61]. Hence, if LPR is a genuine entity with a name suggesting a link to reflux, 
one would anticipate a relationship between increasing BMI and reported throat symptoms. 
The evidence is not clear on BMI effects on throat symptoms. Sone et al administered the RSI 
to 410 attendees of a general health check up in a Japanese population[62]. The rate of 
abnormal RSI scores (RSI>13) was seven percent, with the highest rate found in middle aged 
males with the highest BMI (26 – 28, which is perhaps not high compared to a UK or USA 
population). 
The objective for Chapter 3 is to assess the relationship between the different PROMs and 
clinician rated throat appearances with one another. 
 Methods 
The relationship analysis included age, BMI, RSI, CReSS, LPR-HRQL (overall impact of 
acid reflux score) and RFS. To assess whether the questionnaires’ data were related, the raw 
data was plotted graphically as scatter diagrams. The relationship between the questionnaires 
and the RFS was assessed graphically using (bivariate) pairwise scatter plots. The relationship 
was reported using the Pearson correlation coefficient, which is a measure of the strength of 
the linear correlation between two variables. The strength of correlation has been described by 
Evans as: 0.00-0.19 “very weak”, 0.20-0.39 “weak”, 0.40-0.59 “moderate”, 0.60-0.79 
“strong”, 0.80-1.0 “very strong”[63]. Further descriptive statistics and graphical 
representations were considered to aid in the definition of any relationships that emerged. 
 Results 
Table 3-1 displays the correlation results of age, BMI, RSI, CReSS and LPR-HRQL with one 
another. Increasing age was significantly negatively correlated with both the CReSS and LPR-
HRQL, but not with the RSI. Patients’ BMI was not related to age or any of the three PROMs. 
The RSI was strongly positively correlated with the CReSS and moderately positively 
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correlated with the LPR-HRQL. The CReSS and LPR-HRQL were strongly positively 
correlated. These relationships are displayed graphically in Figure 3-1. Table 3-2 shows the 
correlation of the RFS with the age, BMI and the three questionnaires. The RFS was weakly 
positively correlated with BMI. There was no relationship between the RFS and any of the 3 
symptoms questionnaires 
Table 3-1 Pairwise correlations between of questionnaire outcomes, Age and BMI 
(n=328) 
Variables Age BMI RSI CReSS LPR-HRQL 
Age 1     
BMI 0.08 1    
RSI -0.08 -0.03 1   
CReSS -0.24** 0.02 0.73** 1  
LPR-HRQL -0.29** -0.03 0.58** 0.71** 1 
 
** Correlation is significant at the 0.01 level (2-tailed). 
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Figure 3-1 scatterplot depicting correlation between questionnaire outcomes and Age / 
BMI 
 
Table 3-2 Correlation of RFS with Age, BMI and the questionnaires (n=245) 
 Age BMI RSI CReSS LPR-HRQL 
RFS 0.15* 0.25** 0.06 0.04 -0.02 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
The relationship between the total RFS score and BMI was explored further with descriptive 
analyses and graphically with a box plot (Figure 3-2). Patients BMI were categorised into 
“underweight” (BMI <19), “normal weight” (19 – 24.9), “overweight” (25 – 29.9), “obese” 
(30 – 39.9), “severely obese” (> 40)[64]. Of 325 patients with BMI data, three were 
underweight (0.9%), 91 (27.4%) were normal weight, 133 (40.1%) were overweight, 83 





Figure 3-2  Box plot of BMI categories versus Total RFS score 
 
 Discussion 
The TOPPITS baseline data is comparable to the other studies in suggesting lower symptom 
scores with increasing age. This observation has been demonstrated previously with the RSI 
[27, 60]. However, when analysing the TOPPITs data, increasing age was related to a lower 
score with the CReSS and LPR-HRQL but not the RSI. These findings should not be viewed 
as implying that throat symptoms are less troublesome as patients get older. The 
questionnaires used are subjective measures of symptom burden; how individual patients 
score a symptom on a Likert scale is determined by themselves alone. One plausible 
explanation for these results could be that as patients become older, they develop co-
morbidities that may alter their perception of their throat symptoms relative to other 
symptoms. It is more likely that as patients grow older, the scores they report are lower, rather 
than them reporting fewer symptoms with increasing age. BMI was not related to any of the 
three symptom questionnaires but there was a suggestion of a weakly positive correlation with 
the RFS (discussed further below). 
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As may have been expected, the three symptom questionnaires were related in scoring 
outcomes. The RSI and CReSS were strongly correlated, likewise the CReSS and LPR-
HRQL, and the RSI and LPR HRQL showed moderate correlation. Whilst there are specific 
criteria, as set out in section 1.3.1 (Instrument validation in throat symptoms), to aid 
validation of instruments, the strong correlation between the RSI and CReSS probably 
suggests that only one of these questionnaires need be utilised. The same could be argued for 
the LPR-HRQL; perhaps only one questionnaire is required. 
No linear relationship was observed between the RFS and the three questionnaires in this 
study. In comparison to the study by Mesallam et al [26] with 40 patients, the TOPPITS 
baseline data contained RFS and symptoms outcomes for 245 patients. Only one blinded 
assessor of the images was used in TOPPITS; an experienced speech and language professor. 
This ensured a consistent approach to the scoring across a large sample. The RFS could be 
considered a subjective measure. If the single assessor’s approach was to score relatively low 
this could have affected the results. Given the importance of this finding, it may be 
appropriate to repeat the scoring with further blinded assessors and reassess whether the 
results are consistent. However, the lack of any relationship between the RFS and 
questionnaire scores from the TOPPITS population is very clear. As discussed in the thesis 
introduction, the Mesallam et al[26] study had some potential methodological flaws and was 
undertaken on a much smaller group of patients. Unfortunately, the equipment used to capture 
the throat picture was not standardised across the recruiting centres. However, in stark 
contrast to Mesallam et al no relationship was found in the TOPPITS baseline data between 
symptoms and throat / voice box appearances. These findings raise the question of whether 
throat appearances should be used in the assessment and management of patients with 
persistent throat symptoms. Whilst a weak relationship was noted between the RFS and BMI, 
on further analysis it appears that the relationship is influenced by the small “severely obese” 
group of patients, comprising only 15 patients. The box plot usefully demonstrates that the 
total RFS scores are similar across the larger BMI category groups. This relationship is 
unlikely to be of clinical value. 
 Conclusion 
This analysis of the TOPPITS baseline data has shown that the three questionnaires are 
related in terms of total scores and that increasing age is associated with reduced symptom 
reporting. There was no relationship observed in this dataset between the RFS throat scores 
and any of the three symptoms questionnaires. 
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Chapter 4 Exploratory Factor Analysis 
 Introduction 
Thus far the thesis has described the demographics of the TOPPITS population and 
descriptive analyses of the outcomes data. It has demonstrated that the scoring patterns over 
the three symptom questionnaires are positively related and that the symptom scores do not 
correlate with throat appearance. This chapter will explore whether the large number of 
symptoms, for which data exists, can be reduced into more simplified categories that may be 
of clinical utility. If dimension reduction into fewer defined categories is appropriate, these 
categories will then be used in Chapter 5 to explore whether patients can be placed into 
distinct groups as defined by their presenting symptoms.  
Exploratory factor analysis (EFA) is a statistical method used to identify latent constructs or 
factors within a set of measured variables, which groups correlated variables together. 
Amongst a set of measured variables there may be unmeasured reasons as to why certain 
variables correlate or covary; latent constructs. The methodology can reduce a large set of 
items to a reduced number of factors, with each factor comprised of a number of correlated 
items. EFA has no a priori, or predefined, theory as to which items are expected to map to 
which factors. 
The principal aim of this thesis is to explore whether a more clinically meaningful 
classification of patient symptoms can be proposed. TOPPITS has provided a wealth of 
patient reported symptoms that can be analysed as variables. Any clinically meaningful 
classification of symptoms would ideally have a small number of groups within it. Using EFA 
may allow an appropriate reduction of the unwieldy number of symptoms into fewer 
manageable hypothetical groups, which could then be used as a means to explore whether 
distinct groups of patients can be defined with cluster analysis. 
EFA methodology has been used to analyse the three questionnaires, in separate analyses, in 
previously published studies. These are described in further detail within the discussion 
section. Cathcart et al [50] and Printza et al[49] identified two factors within the RSI, both 
studies demonstrating similar individual items grouped together within these two factors. In 
the former study the two factors comprised: 
1. Breathing difficulties or choking, coughing after eating or lying down, troublesome 
cough, difficulty in swallowing, heartburn or indigestion. 
2. Throat clearing, globus, postnasal drip, and hoarseness or voice disorder.  
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Drinnan et al [45] found three factors within the CReSS questionnaire which were 
subsequently defined as: a “gastrointestinal (oesophageal)” factor; an “upper airway factor” – 
relating to cough, breathing, mucus and hoarseness; and an “obstruction / choking and 
globus” factor (pharyngeal or throat). The original study which described the LPR-HRQL 
questionnaire found that each of the five domains had a single factor structure, other than the 
voice domain which was affected by a single reversed scoring item[57], implying that the 
questions in each domain were appropriately grouped. Confirmatory factor analysis is another 
method of factor analysis which assesses how well a study population fits within a model of 
predefined factors. Confirmatory factor analysis was considered for this thesis. However, 
given the relative paucity of EFA studies in persistent throat symptom populations and the 
fact this thesis had an opportunity to analyse three outcome measures combined, EFA was 
chosen to explore the potential factors rather than seeking to confirm previously published 
factors. EFA was chosen over other data-reduction methods such as Principal Component 
Analysis (PCA). While PCA is useful for reducing the number of variables (but does not give 
insight into latent factors), EFA identifies and measures variables that cannot be measured 
directly (i.e. latent variables – the clinically meaningful underlying symptoms). Using EFA 
also allows comparison with the published literature outlined above.  
The objective of this chapter was to explore dimension reduction with the aim of identifying a 
smaller number of meaningful clinical factors. This will be achieved using EFA, firstly by 
conducting an EFA on combined data from the three questionnaires, and secondly by 
conducting an EFA of the three questionnaires individually, in order to allow comparison with 
the previously published studies. 
 Methods 
The following methods are built on recommendations from Costello and Osborne[65]. A 
series of web based tutorials written and filmed by James Gaskin [66-69] proved to be a very 
accessible resource for the practical implementation of these methods.   
 
Exploratory Factor Analysis 
Data from the RSI, CReSS and LPR-HRQL were combined for the EFA. The data was 
cleaned throughout the TOPPITS trial by a team of data managers who raised queries with 
sites and chased up missing data wherever possible. All nine items and all 34 items from the 
RSI and CReSS were included. Only the voice, cough, throat and swallow domain items (29 
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in total) were included from the LPR-HRQL. Whilst the “overall impact of acid” items were 
included in the original construct validity work[57], it was felt that these items were too 
varied in their nature to reasonably comprise one set of related questions. The overall 
thermometer questions that follow each domain were similarly not included. Patients with 
missing data in any one of the items included from the three questionnaires were excluded 
from the analysis.  
EFA was conducted in SPSS version 24. The commands used are detailed in Appendices - 
EFA Methodology in SPSS. The key elements of an EFA are: 
1. Assessing the data to confirm that data reduction methods are appropriate. 
2. Choosing the correct method to extract the factors. 
3. Deciding how many factors to retain for the final model. The use of Eigenvalues and 
Scree Plots are widely used techniques. EFA involves calculations using mathematical 
matrices. Eigenvalues and Eigenvectors are components used to transform 
mathematical matrices of data values. 
4. Choosing the correct rotation method. If all data items are plotted on an x and y graph, 
rotating the axes can allow the data to be more easily interpreted. Two rotation 
methods exist: orthogonal which rotates the axes around the intersection of x and y, 
keeping x and y at right-angles; and oblique rotation which allows the angles between 
x and y to vary from 90 degrees. Orthogonal is more appropriate for uncorrelated data 
and oblique for correlated data. 
5. Assessing the strength of association of each variable within the factors, and deciding 
on loading values above which items are kept within the factor structure. Factor 
loadings describe the correlation between each variable and the underlying factor – the 
higher the value between zero and one, the stronger the correlation. 
In the first step, variables in a factor analysis should be linearly correlated with each other and 
Bartlett’s test of sphericity was used to check for the presence of correlation between 
variables. The Kaiser-Meyer-Olkin (KMO) test is used to measure the sampling adequacy in 
data. Large KMO values (on a scale of zero to one) are desirable as this implies that 
correlations between pairs of variables (potential factors) can be explained by other variables. 
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In step two, the Principal Axis Factoring extraction method was used, as it is appropriate for 
non-normal data. A non-normal extraction method seemed appropriate considering that 
Chapter 2 showed that the individual items of the RSI, when plotted as a histogram with 
overlying normal curve (see Appendices - Demographic Data Analysis), did not appear 
graphically as normally distributed. In addition, the construction of a Likert scoring scale for 
items on the questionnaires means that, for example, a rise from one to two may not 
necessarily be equivalent to a rise from a score of three to four.  
In step three, factors were retained with an eigenvalue greater than one. Additionally, scree 
tests were used to plot the factors’ eigenvalues graphically. Factors lying above the “break” or 
“shoulder” of the curve were retained. Where there was ambiguity if a factor was at or near 
the break in the curve, several factor analyses were run with a differing number of factors to 
assess which produced the “cleanest” pattern matrix; with individual questionnaire items 
loading on to a single factor.  
In step four, Oblique Promax Rotation of the data was used, given the large dataset and the 
expected relationship of the factors, supported by the strong correlation demonstrated between 
the questionnaires in Chapter 3.  
In step five, the suppression of small coefficients was explored where appropriate, to remove 
items with low loading values. Items’ communalities scores were displayed as a measure of 
correlation with other items. Individual items should be > 0.2-0.4 with low to moderate 
communalities acceptable in the 0.4 to 0.7 range. The rotation of the model was used to assess 
if it had converged within 10 iterations, denoting an acceptable EFA. The total variance of the 
model was used to explain how much of the total variance the extracted factors explain.  
The individual items loading onto the factors were displayed within pattern matrices, with the 
loading value of each item per factor displayed. The adequacy of the EFA models was 
considered by assessing for results with no low loading scores (defined in this instance as 
<0.4). If a single item loaded on more than one factor, this was deemed a cross loading item. 
This was considered acceptable if the loadings differ by more than 0.2 across factors. Cross 
loading items were removed and the EFA re-run, if the factor had several strong loading items 
(>0.5). A factor with less than three items was considered to be weak, with five or more 
strongly loading items being ideal. If a clean factor structure was produced, the individual 
factors were named – either according to the specified questions in the tool, or as new latent 
variable groups. The saved factor variables were scored using the regression method, given 
the oblique rotation used. The saved factor score is a standardised score, with a mean for all 
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patients of zero. This factor score can then be utilised as a predictor variable for future 
analyses. 
 Sample size 
Exploratory factor analysis solutions can be problematic with small sample sizes that contain 
items with low communalities scores or low loading values within factors. A general rule of 
thumb that is commonly applied is a ratio of 10 subjects to 1 item[65]. However, Mundfrom 
et al[70] cite a range of recommended ratios from 3:1 subjects: variables to 10:1, and some 
suggestions including a minimum overall sample size - which varies widely. They show that 
the necessary sample size reduces as the ratio of variables to factors increases – i.e. more 
variables. Even with low communalities, if the ratio of variables to factors is 7 or more the 
sample size is no more than 180 individuals. The review does not offer a conclusion on the 
most appropriate sample size to use. Costello and Osborne[65] state that “Strong data in factor 
analysis means uniformly high communalities without cross loadings, plus several variables 
loading strongly on each factor” and to achieve this requires that EFA is a large sample 
technique. The sample size for TOPPITS was calculated based on the primary RSI outcome 
measure at 16 weeks. In this respect, the sample size available for the EFA was pre-defined 
by the trial. However the sample size of TOPPITS (328 patients with no missing data for all 
three questionnaires) offers the opportunity to improve the evidence from EFA of the 3 
questionnaires as it is far larger than the other EFA studies previously cited. 
 Reliability Analysis 
The items in each factor were analysed using Cronbach’s alpha test and the mean factor 
loading score calculated. Cronbach’s alpha gives a measure of how closely related a set of 
variables are. Reliability analysis was performed and assessment made on the factor strength 
if items were removed from the factor. The mean factor loading score was calculated for each 
factor separately, with a value > 0.7 recommended to represent an appropriate factor 
structure[68]. 
 Separate Questionnaire EFAs 
Separate EFAs for the three individual questionnaires were conducted following the 
methodology described above. This will give the opportunity to compare the TOPPITS 
population EFA with the previously published results. 
 Abbreviations used in EFA tables 
The RSI and CReSS symptoms are included within the results table. To aid editing, the longer 
LPR-HRQL items are abbreviated within the results table (Table 4-1). 
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Table 4-1 LPR-HRQL abbreviations 
lprVOICE 1 My Voice Problems Make It Difficult For Me To Work 
lprVOICE 2 I Feel Satisfied With The Way My Voice Sounds (Reverse scoring) 
lprVOICE3 Being Hoarse Makes It Hard For Me To Communicate My True Self 
lprVOICE4 My Voice Makes Others Feel Uncomfortable To Listen To Me 
lprVOICE5 I Can’t Sing As Much As I Would Like To Because Of My Voice 
lprVOICE6 I Find It Hard To Meet New People Because Of What They Will Think 
lprVOICE7 The Sound Of My Voice Makes People Think I’m Angry Or Upset 
lprVOICE8 Straining To Talk Is Tiring 
lprVOICE9 I Feel Embarrassed About The Sound Of My Voice 
lprVOICE10 I Avoid Talking Because Of The Effort 
lprVOICE11 My Voice Problems Make It Difficult For Me To Do My Job 
lprVOICE12 I Am Afraid I Might Lose My Voice Forever 
lprCOUGH14  My Coughing Embarrasses Me 
lprCOUGH15 I Avoid Social events Where My Coughing Might Bother Others 
lprCOUGH16 I Have To Leave The Room Because Of My Coughing 
lprCOUGH17 People Think I Am Sick Because Of My Coughing 
lprCOUGH18 My Co-workers Can Hear Me Coming Because Of My Coughing 
lprCOUGH19 I Worry About Having A Coughing Spell At A Bad Time 
lprTHROAT21 People Notice How Much I Have To Clear My Throat 
lprTHROAT22 Clearing My Throat Has A Negative Effect On Sex 
lprTHROAT23 Clearing My Throat Has A Negative Effect On Friendships 
lprTHROAT24 The Need To Clear My Throat Makes It Hard To Talk 
lprTHROAT25 I Feel Frustrated About Having To Clear My Throat So Often 
lprTHROAT26 I Avoid Social Events Because Of The Need To Clear My Throat 
lprSWALLOW28 I Feel A Lump In My Throat Which Makes It Hard To Swallow 
lprSWALLOW29 I Hesitate To Eat In Public Because I Have Trouble Swallowing 
lprSWALLOW30 I Am Afraid Of Choking In My Sleep  
lprSWALLOW31 I Am Bothered By A Burning Feeling In My Throat 







 EFA with factors defined by Eigenvalues > 1 
Twelve patients were excluded from the analysis due to missing data. The EFA was 
performed on data from 332 patients. The combined questionnaires EFA had a subject to 
variable ratio of 332:72. The second item in the voice domain of the LPR-HRQL (LPR 
VOICE 2) had a very low communality value, at 0.20. This may have been a reflection of its 
reverse scoring – the only reverse scoring item in the questionnaires. Therefore this item was 
removed from the analysis. 
The KMO measure of sampling adequacy was 0.91 and Bartlett’s test of sphericity suggests a 
statistically significant linear relationship between variables (approximate Chi-square = 
15832, p<0.001) and thus a factor analysis may provide useful insights into this data. The 
majority of included items had satisfactory communality scores (Table 4-2). There were 
borderline scores for the CReSS items: ‘hiccups’, ‘vomiting’, ‘bad breath’, ‘headache’, ‘back 
pain’, and for the fifth LPR-HRQL voice item (‘I can’t sing as much as I would like to 
because of my voice’). These items were maintained in the initial EFA. 
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Table 4-2 Communalities Scores for EFA Combined Questionnaires - Unspecified 




RSI Hoarseness or problem with voice 0.73 
RSI Throat Clear 0.56 
RSI Excess Throat Mucus or PND 0.66 
RSI Difficulty Swallowing Food Liquids or Tablets 0.74 
RSI Cough after Eating or Lying 0.72 
RSI Breathing Difficulties or Choking Episodes 0.62 
RSI Troublesome Cough 0.61 
RSI Something Caught or Lump In Throat 0.63 
RSI Heartburn Chest Pain Indigestion or Stomach Acid Coming Up 0.73 
CReSS Heartburn 0.75 
CReSS Pressure in Chest 0.47 
CReSS Regurgitation 0.50 
CReSS Acid Sour Mouth 0.58 
CReSS Gurgling Stomach 0.48 
CReSS Lump in Throat 0.69 
CReSS Difficulty Swallowing Food 0.82 
CReSS Difficulty Swallowing Liquids 0.55 
CReSS Nausea 0.49 
CReSS Pain in Throat 0.46 
CReSS Vomiting 0.34 
CReSS Bloating 0.47 
CReSS Belching 0.61 
CReSS Flatulence 0.56 
CReSS Hiccups 0.37 
CReSS Decreased Appetite 0.53 
CReSS Rush of Saliva 0.45 
CReSS Feeling Full Early 0.57 
CReSS Bad Breath 0.32 
CReSS Back Pain 0.34 
CReSS Headache 0.29 
CReSS Choking 0.55 
CReSS Cough Upright 0.73 
CReSS Cough after Eating 0.62 
CReSS Cough Lying 0.62 
CReSS Wheezing 0.55 
CReSS Difficulty Breathing 0.74 
CReSS Hoarseness 0.78 
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CReSS Throat Clearing 0.69 
CReSS Excess Mucus 0.78 
CReSS Mucus Dripping 0.72 
CReSS Feeling Things Stuck Throat 0.64 
CReSS Indigestion 0.70 
CReSS Stomach Acid Up 0.77 
lprVOICE 1 0.70 
lprVOICE 3 0.73 
lprVOICE 4 0.71 
lprVOICE 5 0.40 
lprVOICE 6 0.68 
lprVOICE 7 0.60 
lprVOICE 8 0.74 
lprVOICE 9 0.77 
lprVOICE 10 0.73 
lprVOICE 11 0.70 
lprVOICE 12 0.56 
lprCOUGH 14 0.64 
lprCOUGH 15 0.70 
lprCOUGH 16 0.68 
lprCOUGH 17 0.74 
lprCOUGH 18 0.64 
lprCOUGH 19 0.75 
lprTHROAT 21 0.60 
lprTHROAT 22 0.68 
lprTHROAT 23 0.65 
lprTHROAT 24 0.59 
lprTHROAT 25 0.67 
lprTHROAT 26 0.58 
lprSWALLOW 28 0.60 
lprSWALLOW 29 0.59 
lprSWALLOW 30 0.55 
lprSWALLOW 31 0.64 
lprSWALLOW 32 0.58 
 
 
The initial EFA model explained a total variance of 61.6%, and comprised 15 factors. It was 
not a clean factor structure. The scree plot suggested an optimal number of factors between 6 
and 10 (Figure 4-1). The EFA model was incrementally improved through a series of 15 
steps, removing problematic loading items at each stage, with each change resulting in a 
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cleaner factor model. The individual steps and the items removed are detailed in “EFA of 
three questionnaires with factors defined by Eigenvalues > 1” of the Appendix. 
This then gave a 10 factor model (see appendix Table 7-1) with several items cross loading 
onto more than one factor. However, all the cross loading items had a strong loading score on 
one factor and low scores on the cross loading factor. These items were preserved therefore in 
the model. 
Figure 4-1 Scree plot of items’ eigenvalues – Combined questionnaires EFA with 
unspecified number of factors 
 
 
 Defined number of variables EFA 
The above methodology was repeated up to the resultant 10 factor model stage. The number 
of factors was defined as seven rather than being based on eigenvalues greater than one. The 
scree plot (Figure 4-2) does not have a clear shoulder, but would suggest between six and 
eight factors may be a reasonable number to include. The extraction method remained as 
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Principal Axis Factoring, with Promax rotation with Kaiser Normalisation.  Small coefficients 
were supressed to > 0.4 values. 
This produced a model with a KMO of 0.90. All communalities were greater than 0.44 (see 
appendix Table 7-2). The total variance explained by this model was 55%. The rotation 
converged in 9 iterations. ‘CReSS Wheezing’ and ‘CReSS flatulence’ did not load with scores 
>0.40 and were removed. 
Figure 4-2 Scree plot for combined questionnaires EFA - seven factor model 
 
Table 4-3 Pattern Matrix for seven Factor model 
Questionnaire Item 
Factor 
1 2 3 4 5 6 7 
lprVOICE 8 0.90       
lprVOICE 3 0.88       
lprVOICE 9 0.85       
lprVOICE 4 0.81       
lprVOICE 10 0.78       
CReSS Hoarseness 0.76       
lprVOICE 1 0.75       
RSI Hoarseness 0.75       
lprVOICE 6 0.68       
lprVOICE 12 0.65       
lprVOICE 5 0.60       
lprVOICE 7 0.60       
RSI Troublesome Cough  0.85      
CReSS Cough Upright  0.85      
RSI Cough after Eating or Lying  0.83      
CReSS Cough Lying  0.78      




1 2 3 4 5 6 7 
lprCOUGH 17  0.69      
lprCOUGH 19  0.67      
lprCOUGH 16  0.62      
lprCOUGH 18  0.53      
CReSS Indigestion   0.87     
RSI Heartburn,ChestPain, Indigestion,Stomach Acid   0.87     
CReSS Stomach Acid Coming Up   0.86     
CReSS Heartburn   0.86     
CReSS Acid Sour Mouth   0.63     
CReSS Regurgitation   0.54     
CReSS Belching   0.53     
CReSS Bloating   0.46     
CReSS Excess Mucus    0.77    
CReSS Throat Clearing    0.74    
RSI Excess Throat Mucus or PND    0.71    
RSI Throat Clear    0.70    
CReSS Mucus Dripping    0.67    
lprTHROAT 25    0.56    
lprTHROAT 21    0.50    
CReSS Difficulty Swallowing Food     0.70   




1 2 3 4 5 6 7 
CReSS Choking     0.60   
lprSWALLOW 30     0.58   
RSI_Difficulty Swallowing Food Liquids or Tablets     0.57   
CReSS Difficulty Swallowing Liquids     0.57   
CReSS Difficulty Breathing     0.53   
RSI Breathing Difficulties or Choking Episodes     0.46   
RSI Something Caught or Lump In Throat      0.68  
CReSS Feeling Things Stuck Throat      0.62  
CReSS Lump in Throat      0.62  
lprTHROAT 23       0.70 
lprTHROAT 22       0.58 
lprTHROAT 26       0.53 
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 Re-labelling of Factors 
Examining the question items within each factor reveals that the symptoms do seem to link 
together logically. It is useful to give the factors more clinically meaningful names. 
Factor 1 Voice Factor 
Factor 2 Cough Factor 
Factor 3 Gastrointestinal Symptoms (GI) Factor 
Factor 4 Airway Symptoms and Dysphagia Factor 
Factor 5 Throat Clearing Factor 
Factor 6 Lump in Throat Factor 
Factor 7 Life Events Factor 
 
 Reliability Analysis 
Table 4-4 shows the reliability analysis for the seven factor EFA model. The correlation of 
variables within each factor and the mean loading score appeared stronger the greater the 
number of variables contained in each factor. Only one factor would improve, in terms of 
correlation of variables, if items were removed. The seventh factor of Life events would 
increase from Cronbach’s alpha of 0.77 to 0.80 if LPR Throat 26 was removed (I avoid social 
events). This improvement in the Cronbach’s alphas score does not seem significant enough 
to justify dropping the item, which would leave a factor with only two items. The fact that the 
removal of any other items would not improve the correlation of variables with the factors 




Table 4-4 Reliability analysis for the seven factor EFA model 








1 Voice 0.94 0.75 No 
2 Cough 0.92 0.73 No 
3 Gastrointestinal 0.89 0.70 No 
4 Airway / 
Dysphagia 
0.83 0.59 No 
5 Throat clearing 
/ Mucus 
0.85 0.65 No 
6 Life events 077 0.63 Yes 
7 Lump 0.81 0.61 No 
 
 Reflux Symptom Index Exploratory Factor Analysis 
An EFA was conducted for the RSI using the same methods as described above, using 
Principal Axis Factoring with small coefficients suppressed to >0.2, with the number of 
factors defined by Eigenvalues >1. 
The KMO was 0.61 with 41% of the total variance explained (i.e. appreciably lower than the 
values for the combined EFA approach). Communalities were < 0.2 for 3 items (Table 4-5). 
The scree plot did not have shoulder to the curve to indicate a clear number of factors to 
include (Figure 4-3). An initial 3-factor model was produced (Table 4-6). This was not a clean 
factor model, with cross loading scores and low scores evident. The cough items had high 
loading scores in factor 1, difficulty swallowing in factor 2 and excess mucus in factor 3. The 
remaining 5 items in the RSI had low loading scores. 
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RSI Hoarseness or problem with voice 0.12 
RSI Throat Clear 0.21 
RSI Excess Throat Mucus or PND 0.76 
RSI Difficulty Swallowing Food Liquids or Tablets 0.56 
RSI Cough after Eating or Lying 0.60 
RSI Breathing Difficulties or Choking Episodes 0.39 
RSI Troublesome Cough 0.81 
RSI Something Caught or Lump In Throat 0.15 













1 2 3 
RSI Troublesome Cough 0.93 -0.21  
RSI Cough after Eating or Lying 0.66 0.25  
RSI Difficulty Swallowing Food Liquids or Tablets  0.77  
RSI Breathing Difficulties or Choking Episodes 0.28 0.46  
RSI Something Caught or Lump In Throat  0.38  
RSI Excess Throat Mucus or PND   0.90 
RSI Throat Clear 0.21  0.35 
RSI Heartburn Chest Pain Indigestion or Stomach Acid 
  
  0.25 
RSI Hoarseness or problem with voice   0.22 
 
With the number of factors defined as two, the KMO remained at 0.61, with low 
communalities as above for three items. Only 31% of the total variance was explained by this 
model. The scree plot lacked a clear shoulder. The pattern matrix (Table 4-7) did not show a 
clean structure, with only the cough items in factor 1 having high loading scores, and 
difficulty swallowing in factor two. The other six items had low loading score, with two cross 









RSI_TroublesomeCough .78  
RSI_Cough_afterEating_or_Lying .68 .21 
RSI_ThroatClear .42  
RSI_ExcessThroatMucus_orPND .37  
RSI_Hoarseness_or_problem_with_voice .22  
SI_DifficultySwallowingFood_Liquids_orTablets  .81 
RSI_BreathingDifficulties_orChokingEpisodes .36 .43 
RSI_SomethingCaught_orLumpInThroat  .36 
RSI_Heartburn_ChestPain_Indigestion_orStomachAcidComingUp   
 
 CReSS EFA 
Using the defined EFA methodology, the KMO was 0.89 with communalities for all items > 
0.3 (Table 7-3), and total variance explained of 52%. Table 7-4 shows the initial pattern 
matrix with factors extracted with Eigenvalues >1. 
The scree plot is shown in Figure 7-10 and lacks a clear shoulder to define the number of 
factors to include. With the number of factors suppressed to three, in line with Drinnan et 
al[45], the model gave a KMO of 0.89, with similarly high communalities as above. The total 
variance explained was 37%. The pattern matrix is shown in the appendix Table 7-5. 
Cross loading factors with low scores were removed or suppressed by raising the small 
coefficient score to 0.3, to give a cleaner three factor model (Table 4-7). This removed: 
‘feeling full early’, ‘pressure in chest’, ‘vomiting’ and the low scoring cross loadings were 
suppressed: ‘back pain’, ‘hiccups’ and ‘bad breath’. The KMO for this model was 0.89 with 
the total variance explained of 38%. The ‘back pain’ and ‘hoarseness’ item communalities 
were slightly below 0.3, but remained satisfactory. The resulting three factor model could be 
re-labelled as factor one – Gastroesophageal symptom, factor two – Upper Airway symptoms, 
and factor three – Pharyngeal symptoms. 
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Table 4-8 CReSS three Factor Cleaned EFA Pattern Matrix 
Questionnaire Item 
Factor 
1 2 3 
CReSS_Indigestion 0.90   
CReSS_Stomach acid up 0.87   
CReSS_Heartburn 0.82   
CReSS_Acid or sour taste in mouth 0.67   
CReSS_Regurgitation 0.61   
CReSS_Belching 0.59   
CReSS_Bloating 0.55   
CReSS_Gurgling stomach 0.51   
CReSS_Flatulence 0.40   
CReSS_Nausea 0.38   
CReSS_Rush of saliva in mouth 0.34   
CReSS_Coughing when upright  0.86  
CReSS_Cough when lying  0.75  
CReSS_Coughing after eating  0.72  
CReSS_Wheezing  0.65  
CReSS_Mucus dripping in throat  0.51  
CReSS_Excess mucus  0.51  
CReSS_Difficulty breathing  0.47  
CReSS_Throat clearing  0.44  
CReSS_Hoarseness  0.34  
CReSS_Difficulty swallowing food   0.86 
CReSS_Difficulty swallowing liquids   0.74 
CReSS_Lump in throat   0.59 
CReSS_Feeling things stuck throat   0.55 
CReSS_Pain in throat   0.47 
CReSS_Choking  0.34 0.46 
CReSS_Decreased appetite   0.45 
CReSS_Headache   0.33 
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Given the reproducible results from the CReSS questionnaire EFA when compared to the 
published literature, a three factor model for all three questionnaires was performed. The EFA 
methodology was repeated with suppression of coefficients to 0.3. Whilst three factors could 
be demonstrated, the CReSS items were distributed differently to the EFA of this 
questionnaire alone. The 3 factors were Cough and Throat Clear factor, a Voice factor, and a 
Gastrointestinal factor. The CReSS hoarse item was separate to the other CReSS items which 
are distributed among the other two factors. This three factor model for all three 
questionnaires did not appear as applicable as the 7 factor model detailed above.  
 
 LPR-HRQL EFA 
Following the above EFA methodology, the initial model based on factor extraction with 
eigenvalues greater than one gave a KMO of 0.91, communalities were all > 0.3, and the total 
variance explained was 59%. Table 4-8 shows the initial pattern matrix. 
‘Throat 24’ cross loaded with the voice items (‘the need to clear my throat makes it hard to 
talk’). Removing this item did not alter the pattern matrix significantly. The Throat items 




Table 4-9 LPR-HRQL EFA Pattern Matrix 
Questionnaire Item 
Factor 
1 2 3 4 5 
lprVOICE8 0.91     
lprVOICE3 0.86     
lprVOICE9 0.84     
lprVOICE1 0.83    -0.38 
lprVOICE10 0.81     
lprVOICE11 0.80    -0.25 
lprVOICE4 0.78     
lprVOICE6 0.72    0.29 
lprVOICE12 0.66     
lprVOICE5 0.61     
lprVOICE7 0.58    0.21 
lprCOUGH19  0.87    
lprCOUGH16  0.87    
lprCOUGH17  0.85    
lprCOUGH18  0.71    
lprCOUGH14  0.66  0.24  
lprCOUGH15  0.64   0.32 
lprSWALLOW30   0.73   
lprSWALLOW29   0.63   
lprSWALLOW28   0.60   
lprSWALLOW32   0.58   
lprSWALLOW31   0.55   
lprTHROAT25    0.81  
lprTHROAT21    0.70  
lprTHROAT24 0.38   0.41  
lprTHROAT23     0.67 
lprTHROAT22     0.62 





This chapter significantly adds to the evidence base on latent constructs within throat 
symptoms in questionnaire reporting. By combining the RSI, CReSS and LPR-HRQL 
questionnaires together within an EFA, it offers the opportunity to compare the factor 
structure, over many symptom items within a large sample size, with the factor structure 
observed within the individual questionnaires. However, there is great overlap between the 
questionnaires in terms of symptoms, and the relationship analysis performed in Chapter 3 
showed the strong correlation in scoring between the tools. The subject to variable ratio of 
332:72 is less than 10:1, at 4.6:1.  
The combined EFA demonstrated a reasonably clean seven factor structure with high KMO 
and 55% of the total variance explained by this model. The relabelled factors of Voice, 
Cough, Gastrointestinal Symptoms (GI), Airway Symptoms and Dysphagia, Throat Clearing, 
Lump in Throat and Life Events showed high internal correlation between the items within 
each factor. The removal of any items from the factors would not have offered improved 
correlation of items. The first three factors had adequately high mean loading scores. The 
latter four factors had lower mean loading scores. It is not surprising that the first three factors 
appeared strong, given the number of items dedicated to the symptoms of voice, cough and GI 
within the questionnaires. It is interesting to compare the EFA results with the ranked 
symptoms for the RSI and CReSS in Chapter 2. Whereas a feeling of a lump in the throat and 
clearing were the highest ranked individual symptoms, these factors had less items and lower 
correlations and mean loading scores. Again, this may reflect the fact that fewer items relate 
to these symptoms, than for instance gastrointestinal symptoms or voice, within the LPR-
HRQL. 
The following discussion will compare the individual questionnaire EFAs with the published 
literature: 
RSI 
Cathcart et al[50] explored the responses of 227 patients completing the RSI: 134 with catarrh 
symptoms, 61 with voice symptoms and 32 with respiratory disease. Cronbach’s alpha was 
0.75 for all items. A factor analysis using Principal Components Analysis as the extraction 
method, with oblimin rotation and Kaiser normalisation gave three principal components with 
igenvalues  greater than one, but the scree slope suggested a two factor solution was more 
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suitable. Oblimin rotation found the two-factor model to be a neater fit. The two factors found 
were: 
• Breathing difficulties or choking, Coughing after eating or lying down, Troublesome 
cough, Difficulty in swallowing, Heartburn or indigestion (Cronbach’s alpha = 0.75). 
4 of these items had factor loading scores > 0.5. 
• Throat clearing, Globus, Postnasal drip, and Hoarseness or voice disorder. Cronbach’s 
alpha =0.57, increasing to 0.77 when hoarseness was dropped. 3 out of the 4 had > 0.5 
loading scores. 
Printza et al [49]sought to validate a Greek version of the RSI using data from 53 patients and 
172 control subjects. They included a 10th item (throat pain) into the RSI.  They followed the 
methods of Cathcart et al, to use oblimin rotation rather than orthogonal rotation. They also 
identified two factors in the RSI. They found the same two factors as Cathacrt et al, but found 
the globus item weakly loaded to the first factor too (0.27, but 0.62 on the second factor). No 
communality was noted below 0.35. Interestingly whereas hoarseness had been weakly loaded 
to the second factor in Cathcart et al’s study, it was the top item in the second factor (0.92 
loading). Both these studies were of sufficient size with a subject to variable ratio of >10:1. 
Within the TOPPITS population, the RSI appeared the least appropriate data on which to 
conduct an EFA. Assuming an acceptable KMO score of 0.6, this data was just acceptable 
with a score of 0.61. Only 41% of variance was explained which reduced to 31% when the 
factor extraction method was changed from eigenvalues greater than one to a fixed two factor 
model. The three-factor model was not clean. The two-factor model was not cleaned in detail, 
but suggested: 
• Troublesome Cough, Cough after eating or lying down, Throat clearing, Throat mucus 
or post-nasal drip, Hoarseness. 
• Difficulty swallowing, Breathing difficulties, Lump in Throat. 
Breathing difficulties cross loaded with similar loading values, and heartburn did not load 
onto either factor. Whilst there are some similarities between the present RSI EFA and the 
two published EFAs, given only nine items exist in the RSI, concordance between the 
analyses cannot be concluded. There does not appear to be a clear and reproducible factor 
structure to the RSI. 
70 
CReSS EFA 
Interestingly, the EFA for the CReSS with factors defined by eigenvalues greater than one 
produced a similar factor model to the combined questionnaires EFA. However, with only 
one item related to voice within the CReSS, the individual CReSS EFA was not going to 
produce a Voice factor like the combined model. However, the first CReSS EFA did give a 
reasonably clean factor structure.  
Drinnan et al [45] analysed the CReSS scores for 639 patients: 103 controls (staff, friends and 
hearing aid clinic attenders), 359 patients attending for oesophagogastroduodenoscopy 
(OGD), and 177 Ear Nose and Throat patients referred with throat symptoms. They conducted 
an EFA using principal components analysis as the extraction method, with varimax rotation 
(this is orthogonal rotation, but may be more appropriate as the CReSS has a wider range of 
questions, which may not correlate, and the factors may not be correlated as expected for the 
RSI). The subject to variable ratio was 639:34, and therefore >10:1. The CReSS had three 
statistically robust symptom factors: gastrointestinal (oesophageal); an upper airway factor – 
relating to cough, breathing, mucus and hoarseness; and a third, obstruction / choking globus 
factor (pharyngeal or throat)[45].  
When the TOPPITS CReSS EFA was fixed to three factors, a clean structure was obtained 
with omission of only several items, with a high KMO of 0.89. A very similar factor structure 
was identified to that proposed by Drinnan et al[45]. The items within each factor are 
compared between TOPPITS and the previously published EFA by Drinnan et al in Table 
4-10. The 3 items that were within the pharyngeal factor in TOPPITS only were the three 
items with the lowest loading scores. 
 
71 
Table 4-10 CReSS Factor Items within TOPPITS and Drinnan et al 
CReSS Factors Items common to 
both TOPPITS and 
Drinnan et al 
Items only in 
Drinnan et al factor 
model 














Feeling full too early 








Bad breath  
 




















Feeling of things 
stuck in throat 







The single paper to assess the validity of this outcome measure analysed the results of 117 
patients treated with proton-pump inhibitors[48]. Of the three questionnaires, this is the only 
EFA to be conducted solely on patients with throat symptoms. The specific methodological 
details of the factor analysis are not reported, stating a factor analysis of all (five) domains. 
Each domain had one single factor structure, except the voice / hoarse domain. Its second 
factor with an eigenvalue slightly greater than 1 was the reverse scoring item. The subject to 
variable ratio was 117:43 which is appreciably lower than the 10:1 rule of thumb, and less 
than 3:1. The overall sample size of 117 would be considered low for the number of observed 
variables. 
Conducting an EFA on the TOPPITS LPR-HRQL again, materially adds to the evidence base 
on the factor structure of this specific outcome measure, and offers a significantly greater 
population size to draw conclusions from. Whilst the ratio of 332 patients to 43 items is not at 
the 10:1 level suggested earlier, only 29 of the 43 items were included in the present EFA. 
Only the voice, cough, throat and swallow domain items (29 in total) were included from the 
LPR-HRQL. Whilst the “overall impact of acid” items were included in the original construct 
validity work[57], it was felt that these items were too varied in their nature to reasonably 
comprise one set of related questions. The overall thermometer questions that follow each 
domain were similarly not included. The ratio of subjects to variables is therefore >10:1.The 
initial description by Carrau et al[57] did include the “overall impact of acid” items in the 
factor analysis. However, these were not included in the present EFA given the wide variety 
of quality of life aspects covered in these questions.  
The present EFA showed similar results to Carrau et al, with a single factor for each domain 
of questions, other than the Throat domain. There were some items that cross-loaded on to 
two factors with all but one of these having a strong loading score in their domain factor and a 
weaker cross loading score in the other. The one obvious cross loading item was Throat24 – 
“The Need To Clear My Throat Makes It Hard To Talk”. This item does clearly cover both 
throat clearing and voice, and it could be reassuring in terms of the EFA methodology that 
this item cross-loaded to both the voice and throat domain factors. 
The Throat domain remained split over two factors, even with Throat24 removed.  “People 
Notice How Much I Have To Clear My Throat”, “The Need To Clear My Throat Makes It 
Hard To Talk”, “I Feel Frustrated About Having To Clear My Throat So Often” comprised 
one factor, and the other: “Clearing My Throat Has A Negative Effect On Sex”, “Clearing My 
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Throat Has A Negative Effect On Friendships”, “I Avoid Social Events Because Of The Need 
To Clear My Throat”.  The latter three items formed the “life events” factor in the combined 
questionnaire EFA. It is interesting to observe that these three items loaded together in both 
the combined EFA and the individual LPR-HRQL EFA. 
Following the CReSS EFA which demonstrated a reproducible 3 factor model, a similar 3 
factor model applied to all three questionnaires did give an appropriate model. However, it 
was clear that the CReSS item related to a hoarse voice separated from the other CReSS 
items. The inclusion of the LPR-HRQL domains, with its 12 voice related items, will 
certainly have influenced the strength of the hoarse voice factor. However, it is worth 
considering that the CReSS questionnaire containing 34 items may be deficient in voice 
related symptoms. 
 Conclusions 
Chapter 4 has demonstrated a clean seven-factor structure model for an exploratory factor 
analysis on the combined data from the RSI, CReSS and LPR-HRQL. The dimension 
reduction produced through this methodology could be useful to help define categories of 
persistent throat symptoms. The seven factors are clinically meaningful and relevant. As 
would be expected, the factors do categorise the main symptom groups from the 
questionnaires. These seven factors will inform the cluster analysis in Chapter 5. EFA and 
cluster analysis differ, in that EFA groups variables together, whereas cluster analysis groups 
together patients. 
Exploratory Factor Analysis of the individual questionnaires gave poor models for the RSI, 
which were not in agreement with previously published data. The factor structure for the 
CReSS was clean and reproduced the Oesophageal, Upper Airway and Pharyngeal factors 
previously described within this questionnaire. The LPR-HRQL domains do contain one 
factor each, other than the throat domain which suffers with an item covering both voice and 
throat clearing and three questions covering life events which consistently load together as a 




Chapter 5 Cluster Analysis 
 Introduction 
Chapter 4 demonstrated that seven symptom factors emerged from the TOPPITS baseline data 
with individual factors labelled as Voice, Cough, Gastrointestinal Symptoms (GI), Airway 
Symptoms and Dysphagia, Throat Clearing,  Lump in the Throat and Life Events. This 
framework provides a basis for how persistent throat symptoms may be grouped into 
categories. Very little is known about how patients report related throat symptoms. A greater 
understanding or a clinically meaningful classification of related symptoms could aid 
improved management of these conditions. Chapter 5 will explore whether clusters of patients 
can be reliably defined according to their presenting symptoms. Exploratory factor analysis 
and cluster analysis differ in that EFA groups related variables together into factors, and 
cluster analysis groups together patients.  
It is unlikely that a future study will utilise the RSI, CReSS and LPR-HRQL together. 
However, the wealth of symptom data that the three questionnaires has provided from 
TOPPITS could offer greater insights into patient symptom presentations. As in Chapter 4, 
the data from the three questionnaires will initially be analysed together. Cluster analysis 
investigates whether a population consists of distinct groups. Patients in one cluster will be 
similar, in this case on the basis of their throat symptoms, and will differ from patients in the 
other clusters. The seven factors from the exploratory factor analysis will be used as the 
variables to define the patients within the cluster analysis, rather than using all the individual 
symptom items from the three questionnaires. Cluster analysis of all the CReSS items was 
investigated by Papakonstantinou et al, but no distinct clusters of symptoms emerged[44]. A 
defined set of clusters of patients with similar symptom reporting could offer a clinically 
meaningful classification for the population of patients with persistent throat symptoms. 
 Methods 
Cluster analysis techniques group, in this case, patients by assessing how similar they are in 
terms of measured variables. The distance between patients’ scores on the variable of interest 
is measured. The smaller the number, the more similar the patients in terms of reporting that 
particular symptom. In its most simple form, taking the first patient, the first cluster can be 
made with another patient whose symptom score is closest to the first patient. Thereafter 
patients can be join the cluster through linkage techniques: the next patient is similar to the 
last, or the next is similar to either of the patients in the cluster, or the next is similar to the 
average similarity of the patients in the cluster[71]. Another technique is known as Ward’s 
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method, which enters patients into clusters to minimise the variance of the measured variables 
within each cluster[71]. 
The baseline data were analysed using three cluster analysis methods: Two-Step cluster 
analysis, K-means cluster analysis and the Hierarchical method. Of the 3 options, K-means 
analysis is a non-hierarchical method, there is a specific hierarchical method, and the Two-
step analysis is a mix of both non-hierarchical and hierarchical methods. Non-hierarchical 
methods, in which the relationship between clusters is undetermined, would seem appropriate. 
However, hierarchical methods are more frequently used in this type of analysis and were 
used in the previous CReSS cluster analysis[44].  
The factor score variables included in the cluster analysis were incorporated as standardised 
values, produced from the exploratory factor analysis in Chapter 4. Using standardised values 
allows the results to be interpreted with ease and ensures all variables contribute evenly to a 
scale; Standardised factor scores were computed such that they had mean of zero and standard 
deviation of one. The value of each score is a measure of the spread from the group mean, as a 
proportion of the standard deviation. Cluster analysis was performed for the three methods 
initially using all seven factors: Voice, Cough, Gastrointestinal Symptoms (GI), Airway 
Symptoms and Dysphagia, Throat Clearing, Lump in the Throat and Life Events. Cluster 
analysis was performed then with all or a reduced number of factors to establish if a 
reproducible model could be defined over the three methods.  
The number of clusters can either be left open, and automatically defined by the statistical 
analysis, or be specified before the analysis is performed. 
 Two-step Cluster Analysis 
This method initially performs a pre-clustering step to identify groups before running a 
hierarchical clustering algorithm. The log-likelihood distance measure was used, which 
assumes the variables are normally distributed and independent.  The distribution of the 
standardised scores was assessed using histograms with overlying normal curves, alongside 
the skewness and Kurtosis scores. Transformation of the standardised scores was explored if 
they were not normally distributed, to ascertain if the distribution of the standardised scores 
affected the two-step cluster analysis results. 
When the number of clusters was left open, to be automatically determined by the model, both 
Schwartz’s Bayesian Criterion and Akaike’s Information Criteria methods were explored.  
Several graphical outputs are produced in SPSS: 
76 
The Model Viewer produced gives a model summary for the analysis. This gives an indicator 
of cluster quality on a scale of poor to fair to good. This is based on the degree of cohesion of 
the clusters and the silhouette, i.e. the extent to which the clusters overlap or are separate. It 
also gives a pie chart of cluster sizes and a ratio of the largest cluster to smallest cluster; less 
than three is desirable[72]. 
The Predictor Importance output demonstrates how much each variable determines the cluster 
model, and is important in assessing if any strong variables exist that entirely explain the 
cluster model (such as sex).  
The Cluster Comparison output plots the cluster median and interquartile range for each 
variable, overlying the overall population median and interquartile range. The advantage of 
the Two-step analysis over the K-means analysis is the ability to assess easily the range of 
values around the median score for each cluster variable. The cluster membership values can 
be saved as a data output for each patient within SPSS.  
To validate the number of clusters in a two-step cluster analysis, two methods are 
recommended[73]. Firstly, assessing the cluster quality scale between different models that 
vary the number of clusters to be defined. Secondly, through an analysis with automatically 
determined cluster numbers either a Schwartz’s Bayesian Criterion (SBC) an Akaike’s 
Information Criteria (AIC) line graph can be plotted. The pivot table option is chosen, the 
appropriate SBC or AIC values within the table highlighted and a line graph selected. Where 
the line reaches its lowest point depicts the ideal number of clusters to be specified. AIC 
methods are considered to produce more complex outcomes than Bayesian Criterion methods. 
 K-means Cluster Analysis  
Cluster membership was presented graphically using bar charts and the contribution of each 
variable to the cluster solution analysed using analysis of variance (ANOVA). Variables that 
were not significant on ANOVA, and therefore not contributing to a patient’s cluster 
membership, were removed. The number of suitable clusters in the data was expected to be 
between two to five clusters. The number of appropriate clusters for a defined cluster number 
analysis followed the SBC or AIC line graph explored with the Two-step analysis techniques. 
Informally, the K-means model was assessed using the ANOVA table for F values and 
significance, the size of the cluster groups, and the number of iterations required for an 
analysis to converge (should be less than 10 iterations)[74].  
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 Hierarchical Cluster Analysis 
A dendrogram plot was produced. The Wards’ cluster method was used; to produce similar 
sized clusters. It is also an appropriate method for data that has no outliers. Given the Likert 
scale of all the items within the questionnaire, outliers cannot exist - as would be expected 
with a continuous scale such as BMI. The squared Euclidean distance was used for interval 
data, which is the square root of the sum of squared distances between two observations.  
Given the large dataset and the anticipated large dendrogram, precluding inclusion in this 
thesis, the cluster membership number for each patient was used to generate descriptive 
statistics and bar charts of the symptom groups. 95% confidence intervals for the mean factor 
scores within clusters were calculated according to the group mean +/- 1.96 x sd / √n. 
 Comparisons between the cluster analysis techniques 
The three cluster analysis techniques give differing outputs through SPSS. To allow an 
assessment of comparison amongst the techniques a standard output was required. For each 
methodological analysis the cluster membership group for each patient was retained. Box and 
whisker plots were generated to depict the standardised factor scores amongst the cluster 
groups for the three techniques. The box and whisker plots depict the median and interquartile 
range as the box, with the whiskers showing the highest and lowest scores – but which are 
restricted to within 1.5 times the interquartile range. Scores outside that range are shown as 
outliers. 
 Co-variate analysis amongst clusters 
The cluster membership values from each analysis technique were saved as data outputs for 
each patient within SPSS. Definable clusters were plotted graphically against the covariates of 
age and BMI. Scatterplots and box and whisker plots were drawn up to include cluster 
membership, to assess if these covariates differed between symptom cluster groups.  
 
 Cluster analysis of RSI data alone 
The seven factors from the EFA are similar to the structure of the RSI questionnaire. 
Therefore cluster analysis of the most widely used questionnaire, the RSI, was performed to 
ascertain if the findings differ from the above analysis using the defined factors, and also to 




Two clusters were identified when each of the three cluster analysis techniques were used and 
it was specified that the number of clusters should be determined automatically (i.e. number 
of clusters undefined) There was a cluster who scored below the mean or median for all seven 
factor standardised scores and a cluster who scored above the mean or median. This was 
consistent if the number of factor scores included in the analysis was reduced. The results for 
the Two-step analysis and K-means analysis are represented in the Appendices: Figure 7-11, 
Figure 7-12, Figure 7-13, Figure 7-14 and Table 7-6. A two cluster model was not explored 
for the hierarchical methods given these results. The two cluster model was inappropriate to 
draw any further conclusions from. 
To determine how many clusters should be defined in the subsequent analyses, both an AIC 
line graph and a line graph to depict SBC were plotted from data derived from a two-step 
cluster analysis of all seven factor scores (Figure 5-1, Figure 5-2). For the AIC graph, the line 
is steepest to two clusters, and shallows after each additional cluster. However its trough 
appears to be around seven clusters. The SBC line graph is steepest to two, descends further 
to three and is near flat to four, before rising again. Three clusters would appear therefore the 
most appropriate model to explore, with consideration of a four cluster model too. Seven 
clusters was considered too many to offer a clinically meaningful model. 
The number of factors to include in the cluster analyses was explored. The results for all 
seven factors is presented. Exploring fewer factors, prioritising those with the highest mean 
factor loading scores from the exploratory factor analysis, suggested that the three highest 
scored factors: Voice, Cough and Gastrointestinal symptoms may offer a clinically 
meaningful model. The results present these three factor cluster models. 
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Figure 5-1 Line Graph showing Akaike's Information Criteria, derived from a two-step 






Figure 5-2 Line Graph showing Schwarz's Bayesian Criteria, derived from a two-step 





 Two-Step Cluster Analysis with three clusters specified and seven factors included 
The two-step cluster analysis methodology was repeated with three clusters specified rather 
than the number of clusters left open. Figure 5-3, Figure 5-4 and Figure 5-5 show the results 
outputs: This showed a poor to fair model. Voice was the strongest predictor of this model, 
with lump in the throat being the weakest predictor. However, six of the seven factors 
contributed significantly to the model; there was no single factor which dominated and 
influenced the model over the other factors. Cluster one scored below the TOPPITS 
population median across all seven factors, cluster two scored above the median, and cluster 
three scored above the median with several scores lying above the upper quartile for the 
whole population. On closer inspection, cluster two had higher relative GI scores and cluster 
three had relatively higher voice, life events and cough scores. 
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Figure 5-3 Cluster size: Two step cluster analysis for seven factor model with three 














Figure 5-4 Predictor importance: Two step cluster analysis for seven factor model with 














Figure 5-5 Two step cluster analysis: seven factors, three clusters specified 
 
The white boxes represent the median and interquartile range for the population. The lines 
and square dot represent the median and IQR for the cluster. The medians differ to the mean 
of 0 for each factor. 
5.3.1.1 Two-step cluster analysis with 3 clusters specified and the 3 highest factors 
included 
Reducing the number of factors in the cluster analysis model was explored, resulting in the 
three highest loading mean factors: voice, cough and GI symptoms entered into the two –step 
cluster analysis. This model gave a poor to fair cluster quality (Figure 7-15), but with equal 
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sized clusters (Figure 7-16), and the three factors were even in their strength of prediction 
within the model ( Figure 7-17). If the Euclidean Distances measure was used instead of the 
Log-Likelihood measure, the three clusters were unequal in distribution, with one very large 
cluster and two smaller clusters. This option was not considered any further. The results 
outputs are shown in Figure 5-6. Cluster one of 103 patients scored high across the three 
symptoms. All three symptom groups were scored above the population median, but relatively 
higher scores were seen in the cough and voice symptoms than in the GI symptoms. Cluster 
two of 134 patients scored below the population median for all 3 symptom groups. Cluster 
three of 95 patients scored below the population median for cough and voice, but above the 
median for GI symptoms. 
The standardised factor scores are displayed in histograms and overlying normal curves in 
Table 7-7. Not all factors were normally distributed. The standardised scores were 
transformed using a log transformation +8, to ensure all scores were positive. The two-step 
cluster analysis was repeated using these transformed scores. The results did not differ using 
the transformed standardised scores. 
 
Figure 5-6 Two-step cluster analysis with three factors, three clusters specified 
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5.3.1.2 Two-step cluster analysis with three highest factors / symptom groups, four 
clusters specified. 
Figure 7-18 in the appendix shows the model summary for this analysis. The cluster quality 
was particularly poor, which precluded any further cluster analysis or conclusions to be drawn 
from this model.  
 K-Means Cluster Analysis with 3 clusters specified 
The seven-factor K-means cluster analysis methodology was repeated with three clusters 
specified. Figure 5-7 shows the 3 clusters: cluster one of 73 patients with variable scores 
across the seven symptom groups (voice, cough, throat clearing and life events greater than 
the TOPPITS population mean – GI symptoms, airway/ dysphagia and lump in throat lower 
than the population mean), cluster two with 67 patients generally scoring high across the 
symptom groups, and cluster three with 192 patients scoring generally low across the 
symptom groups. This solution converged in nine iterations The ANOVA table showed that 
all seven symptom groups significantly contributed to cluster membership, the Lump in 
Throat again demonstrating the lowest F value (see appendix Table 7-8). 
86 





The K means method was repeated this time with three symptom groups using the highest 
mean factor loading scores from the EFA: Voice, Cough and GI, again - to assess if a reduced 
number of symptoms would offer more straightforward and clinically meaningful clusters. 
This is represented graphically in Figure 5-8. It suggests that cluster one, with 103 patients, 
may have higher reported GI symptoms than the TOPPITS population mean. Cluster two with 
180 patients reported generally lower scores across the three symptom groups. Cluster three 
with 49 patients may have higher reported voice symptoms. This model did not converge after 
10 iterations, hence the analysis may not be appropriate to draw conclusions from. A one-way 
ANOVA with post hoc Bonferoni analysis showed that the GI scores were not significantly 
different between cluster two and three. Table 5-1 shows that all 3 symptom groups had high 
F scores and significantly contributed to patients’ cluster membership. 
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F Sig. Mean Square df Mean Square df 
VOICE Factor 90.61 2 .41 329 221.70 p<0.001 
COUGH Factor 55.34 2 .60 329 91.64 p<0.001 
GI Factor 88.48 2 .39 329 226.94 p<0.001 
df, degrees of freedom; F, F-score, Sig, statistical significance  
 
 Hierarchical Cluster analysis 
5.3.3.1 Hierarchical cluster analysis with clusters specified for seven factors. 
The dendrograms produced from this analysis are not included in the thesis, given their 
physical size to reproduce. When all seven symptom group factors were included, three 
clusters emerged of 131, 116 and 85 patients. Table 5-2, Table 5-3, Table 5-4 and Figure 5-9 
show the raw data and the graphical representation of these 3 clusters. Cluster one scored 
below the overall TOPPITS population mean scores for all seven symptom groups. Cluster 
two scored above the TOPPITS population mean scores for GI symptoms, Throat clearing and 
mucus, and the lump symptom. Cluster three scored above the overall TOPPITS population 
mean scores for all seven symptom groups. 
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Table 5-2 Cluster one: hierarchical cluster analysis for seven factor model 
 n= Minimum Maximum Mean Std. Dev. 
VOICE Factor 131 -.99 1.41 -.42 .59 
COUGH Factor 131 -1.58 1.33 -.60 .65 
GI Factor 131 -1.36 1.84 -.53 .61 
Airway_Dysphagia 
Factor 
131 -1.51 2.67 -.19 .88 
ThroatClear_Mucus 
Factor 
131 -2.12 .46 -.83 .58 
Life Events Factor 131 -1.33 .54 -.50 .35 
Lump Factor 131 -2.79 2.16 -.19 .99 
Std dev, standard deviation. 
Table 5-3 Cluster two: hierarchical cluster analysis for seven factor model 
 n=  Minimum Maximum Mean Std. Dev. 
VOICE Factor 116 -.94 1.81 -.32 .53 
COUGH Factor 116 -1.45 1.98 -.01 .80 
GI Factor 116 -1.35 2.19 .17 .87 
Airway_Dysphagia 
Factor 
116 -1.46 1.48 -.33 .62 
ThroatClear_Mucus 
Factor 
116 -1.78 1.76 .44 .69 
Life Events Factor 116 -1.52 2.10 -.15 .67 
Lump Factor 116 -1.93 2.14 .06 .77 
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Table 5-4 Cluster three: hierarchical cluster analysis for seven factor model 
 n= Minimum Maximum Mean Std. Dev. 
VOICE Factor 85 -.77 3.28 1.09 1.11 
COUGH Factor 85 -1.06 2.61 .94 .84 
GI Factor 85 -1.30 2.91 .58 1.10 
Airway_Dysphagia 
Factor 
85 -1.21 3.34 .74 .98 
ThroatClear_Mucus 
Factor 
85 -1.23 2.03 .67 .75 
Life Events Factor 85 -.96 4.17 .97 1.07 




Figure 5-9 Bar charts to show hierarchical cluster analysis results for three specified 
clusters, on seven factors 
Cluster 1 Cluster 2 
  




5.3.3.2 Hierarchical cluster analysis with three clusters specified for three factors. 
When the 3 highest mean scored factors were included – as in the final Two-step and K means 
analysis including Voice, Cough and GI factors, three clusters emerged of 153, 117 and 62 
patients. Table 5-5, Table 5-6, Table 5-7 and Figure 5-10 show the raw data and the graphical 
representation of these three clusters. Cluster one scored below the overall TOPPITS 
population mean scores for all three symptom groups. Cluster two scored above the TOPPITS 
population mean scores for GI symptoms, at around the population mean for Cough, and 
below the mean for Voice symptoms. Cluster three scored above the overall TOPPITS 
population mean scores for all three symptom groups. There would appear graphical trends 
towards lower GI scores than Voice and Cough in cluster one, and higher Voice scores than 
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Cough and GI symptoms in cluster three. In cluster one the 95% confidence interval for GI 
symptoms did not overlap with those of the voice factor and cough factor. Cluster two was 
clear graphically, and when observing the 95% confidence intervals, in having higher GI 
scores and lower voice scores. The voice factor score in cluster three was higher than the 
cough and GI factors, with non-overlapping 95% confidence intervals when observing the 
voice with the cough and GI factors. 
Table 5-5 Cluster one: hierarchical cluster analysis for three factors 
 N Minimum Maximum Mean Std. Dev. 95% CI 
VOICE Factor 153 -.99 1.41 -.36 .58 -.45 to -.27 
COUGH Factor 153 -1.54 1.98 -.36 .87 -.50 to -.22 
GI Factor 153 -1.36 .27 -.77 .35 -.83 to -.72 
 
Table 5-6 Cluster two: hierarchical cluster analysis for three factors 
 N Minimum Maximum Mean Std. Dev. 95% CIs 
VOICE Factor 117 -.94 .52 -.38 .43 -.46 to -.30 
COUGH Factor 117 -1.58 2.61 .04 .85 -.11 to .19 
GI Factor 117 -.33 2.19 .64 .58 .54 to .75 
 
 
Table 5-7 Cluster three: hierarchical cluster analysis for three factors 
 N Minimum Maximum Mean Std. Dev. 95% CIs 
VOICE Factor 62 -.04 3.28 1.61 .85 1.4 to 1.8 
COUGH Factor 62 -1.06 2.59 .81 .89 .59 to 1.0 




Figure 5-10 Bar charts to show hierarchical cluster analysis results for three specified 
clusters, on three factors 
Cluster 1 Cluster 2 
  





 A comparison of the three cluster analysis techniques 
As shown above, the outputs from each cluster analysis technique differ markedly within 
SPSS. The number of patients in each cluster for each method is shown in Table 5-8. The 
cluster distributions are shown in Figure 5-11, Figure 5-12 and Figure 5-13 for the 3 cluster 
models of the three highest scored factors of Voice, Cough and GI.  
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Table 5-8 Number of patients in each cluster for each cluster analysis technique - three 
specified cluster, three factors 






Cluster 1 103 103 153 
Cluster 2 134 180 117 
Cluster 3 95 49 62 
 
Figure 5-11 Box and whisker plot showing the Two-Step cluster analysis results for 
three factors and three specified clusters 
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Figure 5-12 Box and whisker plot showing the K-means cluster analysis results for three 






Figure 5-13 Box and whisker plot showing the hierarchical cluster analysis results for 
three factors and three specified clusters 
 
 
 Co-variate analysis amongst clusters 
The three clusters defined by the K means analysis using the three factors of voice, cough and 
GI symptoms were saved with their cluster membership values. The relationship between the 
cluster and the demographics of patients within each cluster is graphically displayed in Figure 
5-14. The scatterplot shows no discernible pattern of BMI or age across the three clusters. The 
median, interquartile range and range for the patients’ age in the three clusters appear so 
similar across the clusters that formal analysis was not performed. Likewise, the distribution 
of BMI appears similar across the three clusters. Given the lack of any trends for differences 
in co-variates amongst clusters this analysis was not repeated following the Two-Step or 
Hierarchical cluster analysis techniques. 
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Figure 5-14 Exploring the relationship between cluster and demographics (age and 
BMI). 
Scatterplot of BMI versus Age according to cluster membership groups 
 
 
Box and Whisker plot of age across 3 
cluster groups 
 




 Reflux Symptom Index Questionnaire Cluster Analysis 
5.3.6.1 Two-step RSI cluster analysis 
Line graphs of AIC and SBC are shown in Figure 5-15 and Figure 5-16. The AIC graph 
showed the curve shallows between 3 and 4 clusters. The SBC curve had a trough at three 
clusters. Three cluster were specified therefore for the analyses. Figure 7-19, Figure 7-20 and 
Figure 5-17 show the model outputs. The model had a poor cluster quality. Excess throat 
mucus was the greatest predictor of the model, with heartburn being the least strong predictor 
to the model.  Cluster one of 85 patients scored at or above the population upper quartile for 
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all items except the heartburn item, which scored around the population median. Cluster two 
of 162 patients scored around the population upper quartile for excess mucus and throat 
clearing, around the population median for coughing after eating or lying, throat clearing, 
hoarse voice and heartburn, and around the lower quartile for breathing difficulties / choking, 
swallowing difficulties and troublesome cough. Cluster three of 85 patients scored below the 
population median for six items with swallowing difficulties, lump in the throat and breathing 
difficulties scored near the population median. 
 









Figure 5-17 Two-step cluster analysis for the RSI 
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5.3.6.2 K-means RSI Cluster Analysis 
Repeating the above methodology, standardised values for the nine RSI items were analysed. 
A two cluster model gave a simple split into high (n=194) and low (n=138) scoring clusters 
across all nine items when referenced with the TOPPITS population mean. A 3 cluster model 
gave a cluster of 96 patients scoring below the mean for all items other than cough, a cluster 
of 116 scoring above the mean for all items, and a cluster of 120 scoring below the mean 
other than for difficulty swallowing and something caught in the throat (Figure 5-18). The 
latter model converged within eight iterations and the ANOVA table showed that all nine 
items contributed significantly to the model. 
 






5.3.6.3 Hierarchical cluster analysis of the RSI 
With the number of clusters left unspecified, the analysis produced a two cluster model which 
was inappropriate, as described earlier. A three cluster model was therefore specified, in line 
with the previous results. This gave three clusters of 138, 98 and 96 patients. The raw data is 
presented in the appendix (Table 7-9,Table 7-10 and Table 7-11)and graphical representations 
below (Figure 5-19). 
 
Figure 5-19 Hierarchical cluster analysis of the RSI 


















For all solutions that either yielded or were specified to give a two cluster model, the two 
clusters were consistently split into high and low scoring clusters when compared to the 
overall population median or mean. This is not a particularly useful finding and is a reflection 
of the cluster analysis techniques splitting patients into low and high symptoms reporters, 
based around median scores. When all seven factors, or symptom groups, that emerged from 
the exploratory factor analysis in Chapter 4, were included in the cluster analysis, no clear 
pattern or clinically useful clustering solutions were produced. The analyses using the three 
highest factors appeared to offer clinically meaningful results. 
The two step cluster analysis using the three highest factors with three clusters specified gave 
approximately equal sized clusters, and produced similar results to the K-means in suggesting 
that GI symptoms and voice reporting may offer the potential to distinguish patients’ 
presenting symptoms. The two step analysis showed one cluster reporting higher cough and 
voice symptoms than the GI symptoms and one cluster reporting higher GI symptoms, when 
compared to the major cluster reporting low symptom scores across the three symptom 
groups. The cluster sizes were not the same between the K-means and two-step techniques, 
implying that not all patients mapped to the same cluster between the two methodologies. The 
advantage of the two-step analysis is the data spread that is depicted. In cluster one, the GI 
symptoms mean fell below the upper quartile of the population mean, whereas the cough and 
voice means were above the population means. However the range between the lower and 
upper quartiles for cluster one overlap amongst the three symptoms, which suggests that the 
GI symptoms were not significantly lower than the cough and voice symptoms. In cluster 
three the spread of the GI symptoms did appear to be higher than the spread for the cough and 
voice symptoms, which may suggest that for this cluster of 95 patients GI symptoms were 
reported significantly higher. This is the most that can be inferred when quartile ranges are 
used to compared the spread of data.  
The use of voice symptom reporting as a potential distinguishing outcome emerged in the K-
means analysis using the four factors with the highest mean factor scores. However, the most 
clinically useful solutions appeared when the three highest mean scored factors from the EFA 
were used; Voice, Cough and Gastrointestinal symptoms.  The K-means analysis showed a 
cluster of patients reporting high gastrointestinal symptoms and a cluster reporting high voice 
symptoms, when compared to the major cluster with low scores across the three symptoms 
groups. One disadvantage of the K-means outputs is the inability to assess the spread of the 
data which means that limited conclusions can be drawn from bar charts which lack error 
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bars. The particular three factor K-means model of interest did not converge within 10 
iterations, implying the analysis may not be appropriate to draw conclusions from.  
The hierarchical cluster analysis of the Voice, Cough and GI symptoms, with three clusters 
specified, appeared to support the K-means and Two-step analyses.  With the 95% confidence 
intervals manually calculated, and non-overlapping scores observed, this analysis gave a large 
cluster with lower scores in the three factors than the population mean, a moderate sized 
cluster with markedly higher GI symptoms, and a smaller cluster reporting higher voice 
symptoms. The K-means and hierarchical analyses therefore gave very similar cluster models, 
with the two-step analysis producing a model approaching this too. 
Given the different presentations of the results from the three cluster analysis techniques a 
uniform graphical representation was required to assess if meaningful clusters were consistent 
across the techniques. The box and whisker graphs show that whilst voice and GI symptoms 
emerged as potential distinguishing symptoms between clusters, this finding was not apparent 
when the three techniques were assessed with one another. 
The cluster analyses of the RSI questionnaire did not offer any clinically meaningful results. 
This is in keeping with the study by Papakonstantinou et al who found no identifiable clusters 
within the RSI and CReSS[44].  
 Conclusions 
Cluster analysis techniques have not shown that clinically meaningful groups of patients can 





Chapter 6 Thesis Discussion  
This thesis has explored the wealth of presenting symptoms within a population of patients 
recruited to a large randomised clinical trial. The aims and objectives of the thesis were 
directed at only the baseline data from this trial. During the writing of this thesis, the final 
analysis of the TOPPITS trial was completed. No evidence was found to support the claim 
that stomach acid reduction medication is more effective than placebo in treating persistent 
throat and voice symptoms. Stomach acid reduction medications, in the form of proton-pump 
inhibitors (PPIs), are by far the commonest treatment for these patients. This thesis work has 
therefore taken on greater importance given the lack of evidence to support the efficacy of the 
current most popular method to manage these symptoms. Clinicians will need to readdress 
how to manage patients with persistent throat and voice symptoms, and with that will come a 
need to consider the symptoms in greater detail. This thesis materially adds to the evidence 
and understanding of these symptoms. 
 Statement of principal findings 
Whilst not an aim of this thesis, chapter 2 demonstrates that the results from the TOPPITS 
trial can be applied to any general population of patients with persistent throat and voice 
symptoms. The patients’ demographics and outcome measures scores from the TOPPITS 
baseline data have been described and are comparable to the published literature. The highest 
scored symptoms were those of a lump in the throat, throat clearing and excess throat mucus. 
Traditional heartburn symptoms were not ranked highly and this finding is again in keeping 
with the published literature. The baseline TOPPITS data would therefore appear 
generalisable. As such, the findings from this thesis could also be applied to any other 
population of patients with persistent throat symptoms.  
The RSI, CReSS and LPR-HRQL are related in terms of total scores from this patient 
population. In itself this is not surprising, given the overlap and repetition in the symptoms 
that they cover. It is highly unlikely that a clinical trial will ever use these questionnaires in 
this combination again. At the time of the TOPPITS trial design, the RSI appeared the most 
popular questionnaire to assess throat symptoms. However, clinicians had concerns over its 
brevity, the polysymptomatic reflux question and the fact that previous studies of proton-
pump inhibitors with positive outcomes may have reported such results due to improvements 
in these reflux symptoms alone[56]. The CReSS was used in the trial to include more detailed 
symptoms in its 34 items. The LPR-HRQL was included as it was the only patient reported 
outcome measure specifically aimed at disease-specific quality of life.  
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The demographic data analysis also demonstrated that increasing age was associated with 
reduced symptom score reporting. This was found with the CReSS and LPR-HRQL but not 
with the RSI. This appears to be a consistent finding with similar results reported in previous 
studies using the RSI [27, 60]. 
There was a significant number of patients with missing RFS scores in the baseline data 
analysis. This was discussed by the TOPPITS’ trial management group, who agreed this was 
not due to reporter bias, but rather the throat images were missing for groups of consecutive 
patients from particular institutions. Nevertheless, the TOPPITS RFS data offers by far the 
largest analysis of throat and laryngeal images. In contrast to the most popular cited study of 
40 patients, which showed high concordance between symptoms and throat signs[26], this 
thesis found no association between any of the three questionnaires and the RFS scores in 254 
patients. The RFS was scored by an experienced academic speech and language therapist who 
was blind to the questionnaire scores. Some concerns may be raised as the equipment used to 
capture the images of the throat was not standardised across recruiting centres. The lack of a 
relationship between patient reported symptoms and clinician rated throat appearances calls 
into question the popularity of laryngopharyngeal reflux as a diagnosis.  
Schneider at al [30] assessed the evidence of a causal relationship between reflux and voice 
changes. They used the Bradford-Hill criteria and concluded that the evidence was 
insufficient to prove causality. As described in the introduction to this thesis there is no 
definition for a diagnosis of LPR. Intuitively one would assume the diagnosis would be made 
using a combination of patient reported symptoms, clinical examination and specialist 
investigations. Objective measures of gastroesophageal reflux include pH manometry and 
impedance testing. These measure the pH, frequency and timings of reflux episodes from the 
stomach into the oesophagus. Access to these investigations is often limited and in the UK are 
more widely adopted by surgeons considering gastric anti-reflux surgery. They are not in 
common use in the UK to assess patients with throat and voice symptoms. There is a lack of 
dose –response and temporal relationships between these reflux investigations and symptoms 
[30]. Objective measures of reflux were not used in the TOPPITS trial so as to preserve the 
pragmatic nature of the clinical trial and to maximise recruitment to the study. This thesis 
found no evidence of a relationship between clinical examination findings and patient 
reported symptoms. In essence this suggests that the clinical examination of these patients 
should be focused on excluding defined pathological causes for symptoms, and should not 
focus on throat and laryngeal signs that have been attributed to reflux – as set out in the RFS. 
It would be wise to treat patients on the merits of their symptoms alone, and not on their 
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laryngeal and throat appearances. That is to say, incidental laryngeal appearances found in 
patients who lack persistent throat symptoms should not result in a diagnosis of reflux. The 
lack of coherence between symptoms, signs and investigations should mean that reported 
symptoms form the basis of the clinical consultation and management strategy. 
Gastroesophageal reflux is associated with increasing BMI [61]. This thesis found no 
relationship between throat and voice symptom reporting and BMI. It did find that increasing 
BMI might be related to higher RFS scores. However, this was a weak relationship and the 
lack of coherence otherwise between symptoms, signs and BMI means drawing conclusions 
from this one finding would be inappropriate. The lack of any relationship between BMI and 
throat symptoms in this thesis may again lead us to question whether it is correct to theorise 
that reflux causes throat and voice symptoms. 
Exploratory factor analysis demonstrated seven factors of variables (symptoms) using the 
combined data from the RSI, CReSS and LPR-HRQL. This offers a potential clinically 
meaningful and simplified classification of persistent throat symptoms: voice, cough, 
gastrointestinal symptoms, airway symptoms and dysphagia, throat clearing, life events, and 
lump in the throat sensation The dimension reduction produced through this methodology 
could be useful in future research, such as defining an optimal patient reported outcome tool. 
Exploratory Factor Analysis of the individual questionnaires gave poor models for the RSI, 
which was not in agreement with previously published data. The factor structure for the 
CReSS was clean and reproduced the Oesophageal, Upper Airway and Pharyngeal factors 
previously described for this questionnaire[45]. The LPR-HRQL main symptom domains do 
contain one factor each, other than the throat domain, which suffers with an item covering 
both voice and throat clearing, and three questions covering life events which consistently 
load together as a separate factor. 
Cluster analysis demonstrated separate groups of patients within the TOPPITS population that 
reported a higher burden of gastrointestinal symptoms or a higher burden of voice symptoms. 
However, when the three techniques were compared this finding was not consistent. No 
clinically meaningful clusters of patients were defined. It is therefore reasonable to conclude 
that individual throat and voice symptoms cannot be used to categorise groups of patients 
reliably. A global term that encompasses the range of interlinked symptoms, such as 
persistent throat symptoms, would appear more appropriate than referring to individual 
symptoms. This thesis and the TOPPITS results imply that a broad term like persistent throat 
symptoms is more appropriate to recommend to clinicians than LPR. 
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This thesis has found no definable groups, based on symptoms, which could be used to justify 
subgroup analysis of the TOPPITS final outcomes. 
 Strengths and weaknesses of the study 
The TOPPITS baseline data represents by far the largest sample of patients with persistent 
throat symptoms for whom rigorous prospective outcomes have been collected. The volume 
of missing data was very low. The large sample size allows robust conclusions to be drawn 
from the analyses within this thesis. Concentrating the thesis on only the baseline data within 
TOPPITS has ensured that the presenting symptoms have been analysed independent to any 
of the TOPPITS results. 
Patients entering clinical trials may not represent the general population. We had some 
concerns that patients who had used proton-pump inhibitors previously for heartburn 
complaints may not enter the trial. The ninth item of the RSI, covering traditional reflux 
symptoms, was removed from the inclusion criteria so patients needed to score above 10 on 
the non-heartburn items of the questionnaire. This was done as previous reports of positive 
trial outcomes with PPIs, attributed these results to improvements in the heartburn symptoms 
alone on the RSI[56]. The demographic analysis in chapter 2 clarifies that there is no major 
discrepancy between the TOPPITS population and other populations of persistent throat 
symptoms patients, as evidenced through all-inclusive large case series data, in regards 
symptom reporting and ranking of RSI items. Whilst the exclusion of patients with strong 
heartburn symptoms was a concern, this does not appear to have been born out. As such, the 
thesis results appear applicable to other populations of patients with persistent throat 
symptoms. 
The Exploratory Factor and Cluster analyses have proven useful methods to group symptom 
variables and patients. However, the results from these were influenced by the questionnaire 
constructs. In many ways, the seven factors from the EFA could be viewed as resembling the 
RSI items. The voice factor had the highest mean loading score on the EFA and the greatest 
number of items within a single factor. That was influenced by the 12 voice items from the 
LPR-HRQL. In contrast, the RSI and CReSS only had one voice item each. If the LPR-HRQL 
questionnaire had not been included, then the voice factor may not exist as a single entity but 
may rather load with the other upper airway items. This would have altered the subsequent 
cluster analysis. 
The use of three cluster analysis techniques is not common but can be considered a strength of 
the study. Viewed as independent analyses, the thesis would have concluded that voice and GI 
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symptoms may define groups of patients for subgroup analyses in the TOPPITS trial. 
However when viewed alongside each other the techniques’ results clearly do not offer a 
consistent finding.   
 Unanswered questions and future research 
This thesis has explored presenting throat and voice symptoms. It has not assessed the most 
suitable patient reported outcome measure for this set of symptoms or condition. There are 
clear methods for assessing the utility of PROMs[46]. Now that the TOPPITS trial has 
completed, a future study could reassess the three PROMs used and measure, amongst other 
criteria, the response to change over time or the inter-rater reliability. From the work 
performed in this thesis, the CReSS questionnaire had a more definable factor structure than 
the RSI, which was also very consistent with a previous EFA[45]. However, a number of 
items were omitted for low loading scores from the EFA, and given the thesis results, perhaps 
more emphasis on voice symptoms should be considered. Only one of the 34 items relates to 
hoarseness. There were no major concerns with the LPR-HRQL, but some items cover more 
than one symptom, and only three items were separated as a potential “life events” factor, 
with all the others loading with the symptoms as set out in the RSI or CReSS. So perhaps 
fewer items pertain to disease specific quality of life than were intended. Any tool used 
should be easily managed by patients and clinicians. The structure of the LPR-HRQL and 
scoring system appears unwieldy. A follow on project could assess the most suitable PROM 
for future studies to adopt based on the checklist of criteria and the performances of these 
questionnaire within this clinical trial. These results could then form the basis to commence a 
Core Outcomes Set initiative for patients with persistent throat symptoms. 
A further research project could assess the questionnaire constructs in greater detail, 
incorporating patients’ views. Patient involvement in the questionnaire designs has been 
lacking, and whilst we can hypothesise about for instance how many voice items should be 
included in a 34 item questionnaire, the best way to address this would be through the 
thoughts of the patients. There is, understandably, great variation and subjectivity in how 
patients view the terminology and questions relating to persistent throat symptoms. Medical 
terminology has changed from “unexplained symptoms” to “persistent symptoms” on the 
basis of patients’ input. As the introduction chapter explained, the semantics and 
interpretation over symptoms such as coughing, throat clearing and post nasal secretions are 
not clear. Clarifying patients’ interpretation over these symptoms would be an important first 
step in this research. 
111 
The thesis results can now be taken in context with the TOPPITS results. Many clinicians 
have asked the TOPPITS trial team how they should now manage patients with persistent 
throat symptoms. In response to an NIHR call for Policy Relevant Research, I led a 
multidisciplinary application in October 2019 entitled “Redefining the Management of 
Persistent Throat Symptoms”. The research plan was to disseminate the TOPPITS results 
within primary and specialist secondary care and attempt to offer an alternative patient-
centred approach to managing throat symptoms. Much of the basis for this approach would be 
guided by results from this thesis. We recognise the challenges in altering prescribing 
practices of clinicians, and that a simple message of not giving PPIs will not be as strong as a 
message that offers an alternative strategy. Unfortunately, this bid was unsuccessful, but the 
question of “what next” for these patients in the post-PPI era is clearly of great importance. 
Finally, the results of this thesis are directly relevant to the TOPPITS team. At the time of 
writing this thesis discussion, the emphasis is on publishing the main trial paper and the 
Health Technology Assessment report for the trial. TOPPITS was not designed to perform 
subgroup analysis. The results found no evidence in favour of a PPI over placebo. It may 
therefore be inappropriate to consider any further exploratory subgroup analyses of the trial 
outcomes. This thesis has found no definable clusters of patients to justify subgroup analysis. 
As this thesis is finalised in January 2021, the TOPPITS results are due to be published in the 
British Medical Journal (BMJ). The journal editors have requested that we write an article for 
BMJ Opinions on the topic of persistent throat symptoms and their management. This is very 
timely as the BMJ recently published an educational article aimed at primary care, which 
again recommended PPIs for throat symptoms such as globus sensation. This article generated 
some useful social media discussions. During the current Covid-19 pandemic, doctors have 
consulted patients remotely and we have seen an anecdotal rise in the use of PPIs for throat 
symptoms in primary care. The BMJ is the ideal platform to highlight the TOPPITS results to 
primary care clinicians, and then to allow us to offer an alternative management strategy for 
this large group of patients. Recommending a broad term which removes reflux as a causative 
element from the title, such as “persistent throat symptoms”, will be an important angle to 
cover in changing practice away from PPIs. Persistent throat symptoms could be defined as 
six weeks or more of symptoms that include: globus sensation, intermittent dysphonia, throat 
clearing, catarrh (or “post-nasal drip”), cough (from the larynx level or throat – not lungs), 
and throat discomfort. 
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We acknowledge that further research is required to clarify the role of other anti-reflux 
treatments in managing persistent throat symptoms, such as alginates or life style advice; 
which may include weight loss, avoidance of eating late before bed and raising the head of the 
bed. Offering doctors strategies that involve proven patient delivered therapies to reduce 
throat irritation, throat dryness and throat clearing will be a marked shift from PPI 
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The Outcome Measures 
The Reflux Symptom Index 
Within the last MONTH, how did the following problems affect you?       
0 = no problem   5 = severe problem 
 
Heartburn, indigestion or stomach acid 
coming up 
0 1 2 3 4 5 
 




Hoarseness or a problem with your voice 0 1 2 3 4 5 
Clearing your throat 0 1 2 3 4 5 
Excess throat mucus or postnasal drip 0 1 2 3 4 5 
Difficulty swallowing food, liquids or 
tablets 
0 1 2 3 4 5 
Coughing after eating or lying down 0 1 2 3 4 5 
Breathing difficulties or choking episodes 0 1 2 3 4 5 
Troublesome or annoying cough 0 1 2 3 4 5 
Sensation of something caught in your 
throat or a lump in your throat 
0 1 2 3 4 5 
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 The Comprehensive Reflux Finding Score 
Thank you for agreeing to be in this study.  Please complete the following questions.  
Within the last month, how did the following problems affect you?  
Please tick the box that best fits.  
Symptom  0 
No 
problem 
   
1 2 3 4 5 
Severe 
problem  
heartburn              
pressure in chest              
regurgitation              
acid/sour taste in mouth              
gurgling stomach              
pressure/lump in throat              
difficulty swallowing food              
difficulty swallowing liquids              
nausea              
pain in throat              
vomiting              
bloating              
belching              
flatulence              
hiccups              
decreased appetite              
rush of saliva into mouth       
feeling full too early in a meal              
bad breath              
back pain              
headache              
choking              
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Symptom  0 
No 
problem 
   
1 2 3 4 5 
Severe 
problem  
coughing when upright              
coughing after eating              
coughing when lying down              
wheezing              
difficulty breathing              
hoarseness              
throat clearing              
excess mucus              
mucus dripping down back of throat              
feeling things stuck in throat              
indigestion              
stomach acid coming up              
other – please describe  
  
            
           
  
The Laryngopharyngeal Reflux Health Related Quality of Life 
Questionnaire 
LPR-QOL Questionnaire –©AstraZeneca LP 2003 
Here are some questions about laryngopharyngeal reflux (L R, acid reflux into your upper 
throat, silent reflux) and how it affects you.  
Below most questions you will see numbers from 0 to 6, with a description of how often you 
experience that symptom. If you have a symptom that is described in a question, even if you 
think it is caused by something else (for example, allergies or a cold), please go ahead and 
answer the question anyway.   
If a symptom does not apply to you, then you would circle "0," "None of the time". On the 
other and, if you experienced a symptom all of the time or always, you would circle "6," 
"Nearly all of the time or always."   
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You will notice that after a set of questions that relate to a particular symptom, there is a 
question in bold type rated on a scale from 1 to 10 which asks you to summarize the overall 
impact of those symptoms on your life.   
Finally, at the end of the questionnaire, there are a number of questions that use the 1 to 10 
scale. Please be sure to complete each question by circling the number and description that 
best states your answer. Often your first response that comes to mind is the best one.   
There are no right or wrong answers, and that your answers to the questionnaire will be kept 
confidential.   
Don't forget to answer every question!  
Thank you  
*For the purposes of editing, the scoring descriptions have been removed from the table, as 
they would normally appear, and shown below*. 
Score or LPR-HRQL Description of score in questionnaire 
0 None of the time (never in the past month) 
1 Rarely (once in the past month) 
2 A little of the time (2-3 days in the past month) 
3 Some of the time (about once a week) 
4 A lot of the time (about 2 to 3days a week) 
5 Most of the time  (4-5 days a week) 
6 Nearly of the time or always (6-7 days a week) 
 
OVER THE PAST 4 WEEKS…..  
Please tick the appropriate box.  






4  5  
  
6  
My Voice Problems Make It Difficult For Me To Work               
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I Feel Satisfied With The Way My Voice Sounds               
Being Hoarse Makes It Hard For Me To Communicate My 
True Self 
              
My Voice Makes Others Feel Uncomfortable To Listen To Me 
when I am talking 
              
I Can’t Sing As Much As I Would Like To Because Of My 
Voice  
              
I Find It Hard To Meet New People Because Of What They 
Will Think 
              
The Sound Of My Voice Makes People Think I’m Angry Or 
Upset  
              
Straining To Talk Is Tiring               
I Feel Embarrassed About The Sound Of My Voice                
I Avoid Talking Because Of The Effort               
My Voice Problems Make It Difficult For Me To Do My Job                
I Am Afraid I Might Lose My Voice Forever                
  
Questions 1-12 above were about talking, singing, and your voice. The question below asks 
you to think about how problems with your voice affected your overall quality of life.  
Please rate from 1 to 10, where 1 means "no effect" and 10 means 'an enormous effect," how   
much of an effect have problems with talking, singing and your voice had on your overall    
quality of life?  (circle one).  
1  2  3  4  5  6  7  8  9  10  
 
OVER THE PAST 4 WEEKS…..  
Please tick the appropriate box.  










My Coughing Embarrasses Me                
I Avoid Social events Where My Coughing Might Bother 
Others  
              
I Have To Leave The Room Because Of My Coughing                
People Think I Am Sick Because Of My Coughing                
My Co-workers Can Hear Me Coming Because Of My 
Coughing  
              
I Worry About Having A Coughing Spell At A Bad Time                
 
Questions 14-19 were about coughing. The question below asks you to think about how 
problems with coughing affected your overall quality of life.   
Please rate from 1 to 10, where 1 means "no effect" and 10 means an "enormous effect," how   
much of an effect have coughing had on your overall quality of life?  (circle one). 
  1  2  3  4  5  6  7  8  9  10  
  
OVER THE PAST 4 WEEKS…..Please tick the appropriate box. 






4  5  
  
6  
People Notice How Much I Have To Clear My Throat                
Clearing My Throat Has A Negative Effect On Sex                
Clearing My Throat Has A Negative Effect On Friendships                
The Need To Clear My Throat Makes It Hard To Talk                
 
Questions 21-26 above were about clearing your throat. The question below asks you to think 
about how problems with clearing your throat affected your overall quality of life.   
Please rate from 1 to 10, where 1 means "no effect" and 10 means an "enormous effect," how   
much of an effect problems with clearing your throat had on your overall quality of life?    
(circle one).            
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 1  2  3  4  5  6  7  8  9  10  
  
OVER THE PAST 4 WEEKS…..  
Please tick the appropriate box.  






4  5  
  
6  
I Feel A Lump In My Throat Which Makes It Hard To 
Swallow  
              
I Hesitate To Eat In Public Because I Have Trouble 
Swallowing  
              
I Am Afraid Of Choking In My Sleep                
I Am Bothered By A Burning Feeling In My Throat                
I Awaken From Sleep Gasping For Breath         
 
Questions 28-32 above were about general throat symptoms. The question below asks you to 
think about how problems with general throat symptoms affected your overall quality of life. 
Please rate from 1 to 10, where 1 means "no effect" and 10 means an "enormous effect," how   
much of an effect problems with your throat had on your overall quality of life?  (circle one).              
 1  2  3  4  5  6  7  8  9  10  
  
The remaining questions refer to the combined impact of all of your acid reflux related 
symptoms (acid reflux into your upper throat) on various aspects of your life.  
34. In general, on a scale from 1 to 10, where 1 means "no effect" and 10 means "an 
enormous effect," how much of an effect have symptoms described above had on your energy 
levels? (circle one) 
 1  2  3  4  5  6  7  8  9  10  
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35. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your productivity at 
your job/work? (circle one) 
 1  2  3  4  5  6  7  8  9  10  
36. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your social 
relationships? (circle one) 
1  2  3  4  5  6  7  8  9  10 
37. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your marital/intimate 
relationships? (circle one) 
 1  2  3  4  5  6  7  8  9  10 
38. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your sexual 
relationships?  
 1  2  3  4  5  6  7  8  9  10 
39. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your sleeping? (circle 
one) 
 1  2  3  4  5  6  7  8  9  10 
40. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your ability to lie 
comfortably in bed? (circle one) 
 1  2  3  4  5  6  7  8  9  10 
41. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect,"   how much of an effect have symptoms described above had on the way you feel 
about yourself? (circle one) 
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 1  2  3  4  5  6  7  8  9  10 
42. On a scale from 1 to 10, where 1 means "no effect" and 10 means "an enormous 
effect," how much of an effect have symptoms described above had on your lifestyle (i.e. 
smoking, drinking, exercise, eating habits)? (circle one) 
 1  2  3  4  5  6  7  8  9  10 
43. On a scale from 1 to 10, where 1 means "no interference" and 10 means "a great deal 
of   interference" how much of an effect have symptoms described above interfered with your 
ability to do the things you enjoy? (circle one) 
 1  2  3  4  5  6  7  8  9  10 
 
Thank you for completing this questionnaire  
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 The Reflux Finding Score 
Subglottic Oedema 0 = absent 
2 = present 
Ventricular Obliteration 2 = partial 
4 = complete 
Erythema/hyperaemia 2 = arytenoids only 
4 = diffuse 
Vocal fold Oedema 1 = mild 
2 = moderate 
3 = severe 
4 = polypoid 
Diffuse laryngeal Oedema 1 = mild 
2 = moderate 
3 = severe 
4 = obstructing 
Posterior commissure hypertrophy  1 = mild 
2 = moderate 
3 = severe 
4 = obstructing 
Granuloma/granulation tissue 0 = absent 
2 = present 
Thick endolaryngeal mucus 0 = absent 
2 = present 
 
Demographic Data Analysis 
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Figure 6-1 Histogram and overlying normal curve showing the distribution of the RSI 
item 1 - Hoarseness 
 
Figure 6-2 Histogram and overlying normal curve showing the distribution of the RSI 





Figure 6-3 Histogram and overlying normal curve showing the distribution of the RSI 
item 3 - Difficulty swallowing 
 
Figure 6-4 Histogram and overlying normal curve showing the distribution of the RSI 
item 4 - Excess Throat Mucus and Post Nasal Drip 
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Figure 6-5 Histogram and overlying normal curve showing the distribution of the RSI 
item 5 - Coughing after eating / lying 
 
Figure 6-6 Histogram and overlying normal curve showing the distribution of the RSI 
item 6 - Breathing difficulties / choking 
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Figure 6-7 Histogram and overlying normal curve showing the distribution of the RSI 
item 7 - Troublesome cough 
 
Figure 6-8 Histogram and overlying normal curve showing the distribution of the RSI 
item 8 - Lump in throat 
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Figure 6-9 Histogram and overlying normal curve showing the distribution of the RSI 





Exploratory Factor Analysis Appendices 
EFA Methodology in SPSS 
Choose: Analyse / Dimension reduction / Factor analysis 
Enter variables (All RSI, CReSS and LPR-HRQL – only the 4 symptom domains) 
Descriptives: Choose KMO and Bartlett’s test of sphericity. The KMO (Kaiser-Meyer-Olkin 
measure of sampling adequacy) assesses whether a factor analysis is appropriate for the data 
and should be >0.6. The higher the value, the more appropriate an EFA is to fit the data. The 
Bartlett’s test of sphericity should by significant (<0.05) to support an EFA 
Extraction: The method to choose will depend on the data distribution. Principal Axis 
Factoring is appropriate for non-normal data and Maximal Likelihood for normal data. These 
extraction methods are preferable to the SPSS default choice of Principal Components 
Analysis, as the latter includes both shared and unique variable variance. Principal Axis 
Factoring and Maximal Likelihood include only shared variable variance in the solution. 
Chapter 2 showed that the individual items of the RSI, when plotted as a histogram with 
overlying normal curve (see Chapter 7 Appendices for the graphs), did not appear graphically 
as normally distributed. Also considering the construction of a Likert scoring scale for items 
on the questionnaires in which, for example, a rise from 1 to 2 may not necessarily be 
equivalent to a rise from a score of 3 to 4, it would be appropriate to use the Principal Axis 
Factoring extraction method for non-normally distributed data.  
Display: Scree Plot 
Extract: based on Eigenvalues > 1 
Extraction of factors can be performed by retaining those with an eigenvalue > 1. However, 
this may not be accurate. A scree test plots the factors’ eigenvalues graphically. The steep 
aspect of the curve will contain those factors to be retained. After the “break” or “shoulder” of 
the curve will lie factors contributing less variance. Those factors after the break can be 
removed. Where there is ambiguity if a factor is at or near the break in the curve, several 
factor analyses can be run with a differing number of factors to assess which produces the 
“cleanest pattern matrix”. Rather than extracting based on eigenvalues, the number of factors 
to be included is specified.  
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Rotation: Promax.  
Rotation of the data can either be via an orthogonal (90 degrees) or oblique. Oblique rotation 
is more appropriate for correlated factors. For this thesis, correlation between throat symptom 
factors would be expected. This theory would be supported by the strong correlation 
demonstrated between the questionnaires in Chapter 3. The rotation options in SPSS are 
Direct Oblimin or Promax. Promax has been recommended for large datasets (James Gaskin 
reference).  
Scores:  Nil required 
Options: Suppress small coefficients (should be 0.2 below minimum acceptable loading value 
– eg 0.3 if 0.5 is the desirable minimum item loading to a factor). 
EFA Outputs: Check KMO and sphericity significance. 
Communalities: the figures in the extraction column depict how an item correlates with all the 
other items. Individual items should be > 0.2-0.4. Communalities are considered high if all are 
> 0.8, but that is considered rare. Low to moderate communalities are acceptable in the 0.4 to 
0.7 range. The rotation of the model should converge within 10 iterations to denote an 
acceptable EFA. 
Total variance explained – shows how many factors have been extracted and how much of the 
total variance these factors explain. Use Extraction Sums of Squared Loadings value rather 
than the Initial Eigenvalue percentage variance. 
Assess scree plot and number of factors above 1. The alternative is to take the number of 
factors above the shoulder of the curve of the scree plot, which may not be the same as 
Eigenvalue > 1. 
Pattern Matrix: Individual items are presented in the left hand column, the factors extracted in 
the superior row, with the loading value of each item per factor displayed. The factor 
correlations can be analysed separately, aiming for the separate factors to not correlate with 
one another – the items in each factor should correlate with each other. 
Look for clean factors with no low loading scores (defined in this instance as <0.4): 
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If one single item loads on more than one factor, this is a cross loading item. This is 
acceptable if the loadings differ by more than 0.2. Cross loading items can be removed and 
the EFA re-run, if the factor has several strong loading items (>0.5). 
A factor with less than 3 items is weak. Five or more strongly loading items is ideal. 
When there is a clean factor structure produced, the individual factors can be named – either 
according to the specified questions in the tool, or as new latent variable groups. 
EFA of three questionnaires with factors defined by Eigenvalues > 1 
The following sequence of steps details the items removed in the series of EFA that reduced 
the initial 15 factor model to a cleaner 10 factor model ( Table 7-1). 
• ‘RSI hoarseness’ and ‘CReSS hoarseness’ cross-loaded with factor 1 and they loaded 
with the ‘CReSS pain in the throat’ item in a separate factor. These two items had 
loading scores >0.4 in both factors. ‘CReSS pain in throat’ cross-loaded with ‘I am 
afraid of choking in my sleep’ and ‘I awaken from sleep gasping for breath’ symptoms 
from the LPR HRQL Swallow domain. The ‘CReSS Pain in the Throat’ item was 
removed due to this cross-loading.  
• The LPR Voice 1 and 11 items cross loaded across two factors, both with scores > 0.5. 
These items are very similar in description; ‘My voice makes it difficult to work’ and 
‘my voice makes it difficult to do my job’.  Item 11 was removed and the EFA 
conducted again.  
• The LPR-HRQL Swallow 29 item (‘I hesitate to eat in public because I have trouble 
swallowing’) cross-loaded across two factors with low loading scores, 0.41 and 0.28.  
• The ‘CReSS rush of saliva’ cross-loaded across two factors with low loading scores, 
0.21 and 0.21.  
• The LPR-HRQL Swallow 28 item (‘I feel a lump in my throat which makes it hard to 
swallow’) cross loaded with low scores across four factors, and loaded on a separate 
factor with a number of cough related symptoms from the emerging second factor.  
• The ‘CReSS hiccups’ item cross-loaded with low scores, 0.27 and 0.23. 
• The ‘CReSS back pain’, ‘pressure in chest’ and ‘headache’ items all cross loading 
with low values.  
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• The LPR-HRQL Swallow 31 item (‘I am bothered by burning feeling in my throat’) 
cross-loaded across two factors with low scores, 0.28 and 0.49. 
• The LPR-HRQL Cough 15 item (‘I avoid social events where my coughing might 
bother others’) cross loaded across 3 factors, with scores of 0.49, 0.36 and 0.38. 
• The ‘CReSS feeling full early’ item cross loaded across 3 factors with scores of 0.24, 
0.22 and 0.22.  
• The ‘CReSS decreased appetite’ item cross-loaded with low scores, 0.29 and 0.21. 
• The ‘CReSS vomiting’ item cross-loaded and low scores, 0.34 and 0.24. The ‘CReSS 
nausea’ item cross-loaded with low scores, 0.27 and 0.25. Both items were removed 
before the EFA was repeated. 
• At this stage there were 10 items forming the second factor, which appeared to relate 
to cough. Five of these items loaded on a second common factor with the LPR-HRQL 
Cough 14 item cross loading over 3 factors, with scores of 0.59, 0.34 and 0.27. This 
item was therefore removed. This removal split the second cough factor into 2 
separate factors. 
• The LPR-HRQL Throat 24 item (‘The need to clear my throat makes it hard to talk’) 
cross-loaded over two factors, which is understandable from the phraseology covering 
voice and throat clearing). The loading scores were 0.42 and 0.37. This removal 
brought the cough related items back into one factor. 
• The ‘CReSS bad breath’ item was a low score on one factor, 0.28. The ‘CReSS 





Table 7-1 Ten factor EFA model – Pattern Matrix 
Questionnaire Item 
Factor Number 
1 2 3 4 5 6 7 8 9 10 
lprVOICE8 0.90          
lprVOICE3 0.87          
lprVOICE9 0.84          
lprVOICE_4 0.81          
lprVOICE10 0.78          
lprVOICE 1 0.75          
CReSS_Hoarseness 0.74    0.21    -0.27  
RSI_Hoarseness_ 0.73        -0.26  
lprVOICE6 0.70        0.25  
lprVOICE12 0.64          
lprVOICE 5 0.61          
lprVOICE 7 0.60          
CReSS_Cough Upright  0.81         
RSI_Cough-after Eating / Lying  0.78         
lprCOUGH 17  0.78         
RSI_Troublesome Cough  0.78    -0.24     
lprCOUGH 19  0.76         
CReSS_CoughLying  0.74         
lprCOUGH 16  0.72         
CReSS_CoughafterEating  0.67         
lprCOUGH 18  0.65         
CReSS_Heartburn   0.92        
RSI_Heartburn_   0.90        
 
CReSS_StomachAcidUp   0.86        
CReSS_Indigestion   0.79        
CReSS_AcidSourMouth   0.59        
CReSS_Regurgitation   0.44        
CReSS_DifficultyBreathing    0.84       
lprSWALLOW 32    0.63       
lprSWALLOW 30    0.59       
RSI_BreathingDifficulties_orChokingEpisodes    0.56       
CReSS_Wheezing    0.54       
CReSS_Choking    0.54  0.23     
CReSS_ThroatClearing     0.79      
RSI_ThroatClear     0.73      
lprTHROAT 25     0.68    0.28  
lprTHROAT 21     0.60    0.36  
CReSS_DifficultySwalFood      0.91     
RSI_DifficultySwallowingFood_Liquids      0.81   -0.20  
CReSS_DifficultySwalLiquids      0.71     
CReSS_ExcessMucus       0.91    
CReSS_MucusDripping       0.76    
RSI_ExcessThroatMucus_orPND       0.75    
RSI_SomethingCaught_orLumpInThroat        0.90   
CReSS_LumpinThroat        0.67   
CReSS_FeelingThingsStuckThroat        0.67   
lprTHROAT 23         0.68  
lprTHROAT 22         0.58  
lprTHROAT 26         0.52  
CReSS_Belching          0.73 
CReSS_Flatulence          0.71 
 




Table 7-2 EFA communalities - Combined Questionnaires. seven factors specified 
Questionnaire Item Extraction 
 RSI Hoarseness or problem with voice 0.58 
RSI Throat Clear 0.52 
RSI Excess Throat Mucus or PND 0.53 
RSI Difficulty Swallowing Food Liquids or Tablets 0.53 
RSI Cough after Eating or Lying 0.63 
RSI Breathing Difficulties or Choking Episodes 0.41 
RSI Troublesome Cough 0.60 
RSI Something Caught or Lump In Throat 0.49 
RSI Heartburn Chest Pain Indigestion or Stomach Acid Coming Up 0.66 
CReSS Heartburn 0.67 
CReSS Regurgitation 0.46 
CReSS Acid Sour Mouth 0.51 
CReSS Lump in Throat 0.50 
CReSS Difficulty Swallowing Food 0.64 
CReSS Difficulty Swallowing Liquids 0.42 
CReSS Bloating 0.31 
CReSS Belching 0.38 
CReSS Flatulence 0.21 
CReSS Choking 0.49 
CReSS Cough Upright 0.68 
CReSS Cough after Eating 0.57 
CReSS Cough Lying 0.62 
CReSS Wheezing 0.43 
CReSS Difficulty Breathing 0.44 
CReSS Hoarseness 0.61 
CReSS ThroatClearing 0.62 
CReSS ExcessMucus 0.63 
CReSS MucusDripping 0.61 
CReSS FeelingThingsStuckThroat 0.57 
CReSS Indigestion 0.69 
CReSS StomachAcidUp 0.72 
lprVOICE 1 My Voice Problems Make It Difficult For Me To Work 0.52 
lprVOICE 3 Being Hoarse Makes It Hard For Me To Communicate My True Self 0.70 
lprVOICE 4 My Voice Makes Others Feel Uncomfortable To Listen To Me 0.67 
lprVOICE 5 I Can’t Sing As Much As I Would Like To Because Of My Voice 0.39 
lprVOICE 6 I Find It Hard To Meet New People Because Of What They Will Think 0.63 
lprVOICE 7  The Sound Of My Voice Makes People Think I’m Angry Or Upset 0.51 
lprVOICE 8 Straining To Talk Is Tiring 0.74 
lprVOICE 9 I Feel Embarrassed About The Sound Of My Voice 0.74 
lprVOICE 10 I Avoid Talking Because Of The Effort 0.67 
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lprVOICE 12 I Am Afraid I Might Lose My Voice Forever 0.53 
lprCOUGH 16 I Have To Leave The Room Because Of My Coughing 0.56 
lprCOUGH 17 People Think I Am Sick Because Of My Coughing 0.65 
lprCOUGH 18 My Co-workers Can Hear Me Coming Because Of My Coughing 0.52 
lprCOUGH 19 I Worry About Having A Coughing Spell At A Bad Time 0.64 
lprTHROAT 21 People Notice How Much I Have To Clear My Throat 0.52 
lprTHROAT 22 Clearing My Throat Has A Negative Effect On Sex 0.48 
lprTHROAT 23 Clearing My Throat Has A Negative Effect On Friendships 0.59 
lprTHROAT 25 I Feel Frustrated About Having To Clear My Throat So Often 0.56 
lprTHROAT 26 I Avoid Social Events Because Of The Need To Clear My Throat 0.47 
lprSWALLOW 30 I Am Afraid Of Choking In My Sleep  0.41 
lprSWALLOW 32 I Awaken From Sleep Gasping For Breath 0.43 
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Table 7-3 CReSS EFA communalities scores 




CReSS_Acid  SourMouth 0.54 
CReSS_Gurgling Stomach 0.48 
CReSS_Lump in Throat 0.64 
CReSS_Difficulty Swallowing Food 0.75 
CReSS_Difficulty Swallowing Liquids 0.60 
CReSS_Nausea 0.46 






CReSS_Decreased Appetite 0.49 
CReSS_Rush of Saliva 0.41 
CReSS_Feeling Full Early 0.54 
CReSS_Bad Breath 0.28 
CReSS_Back Pain 0.25 
CReSS_Headache 0.25 
CReSS_Choking 0.40 
CReSS_Cough Upright 0.78 
CReSS_Cough after Eating 0.63 
CReSS_Cough Lying 0.61 
CReSS_Wheezing 0.59 
CReSS_Difficulty Breathing 0.54 
CReSS_Hoarseness 0.22 
CReSS_Throat Clearing 0.42 
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CReSS_Excess Mucus 0.75 
CReSS_Mucus Dripping 0.66 
CReSS_Feeling Things Stuck Throat 0.56 
CReSS_Indigestion 0.72 
CReSS_Stomach Acid coming Up 0.74 
 
Figure 6-10 CReSS EFA Scree Plot 
 
 
Table 7-4 CReSS EFA Pattern Matrix 
Questionnaire Item 
Factor 
1 2 3 4 5 6 7 8 
CReSS_Heartburn 0.95               
CReSS_Stomach acid coming up 0.86               
CReSS_Indigestion 0.81               
CReSS_Acid or sour taste in Mouth 0.46 0.33             
CReSS_Vomiting   0.68       -0.23     
CReSS_Feeling Full Early   0.65 0.22           
CReSS_Decreased Appetite   0.62             
CReSS_Nausea   0.50             
CReSS_Hiccups   0.43             
CReSS_Headache   0.41             
CReSS_Rush of saliva in mouth   0.40             
CReSS_Regurgitation 0.35 0.40             
CReSS_Bad Breath   0.39             
 
CReSS_Difficulty breathing     0.70           
CReSS_Wheezing     0.64 0.22         
CReSS_Pressure in chest     0.62       0.23   
CReSS_Hoarseness     0.34           
CReSS_Back pain   0.24 0.31           
CReSS_Coughing when upright       0.88         
CReSS_Coughing after eating       0.74         
CReSS_Coughing lying down       0.72         
CReSS_Excess mucus         0.92       
CReSS_Mucus dripping in throat         0.77       
CReSS_Throat clearing         0.58 0.20     
CReSS_Flatulence           0.82     
CReSS_Belching           0.71     
CReSS_Gurgling stomach           0.51   0.21 
CReSS_Bloating           0.47     
CReSS_Lump in throat             0.77   
 
CReSS_Feeling things stuck in throat             0.64   
CReSS_Pain in throat             0.30   
CReSS_Difficulty swallowing food               0.83 
CReSS_Difficulty swallowing liquids               0.73 




Table 7-5 CReSS three Factor EFA Pattern Matrix 
Questionnaire Item 
Factor 
1 2 3 
CReSS_Indigestion 0.92   
CReSS_Stomach acid coming up 0.88   
CReSS_Heartburn 0.82   
CReSS_Acid or sour taste in mouth 0.67   
CReSS_Regurgitation 0.61   
CReSS_Belching 0.60   
CReSS_Bloating 0.56   
CReSS_Gurgling stomach 0.51   
CReSS_Flatulence 0.41   
CReSS_Nausea 0.38  0.30 
CReSS_Feeling full early 0.37  0.31 
CReSS_Rush of saliva 0.34 0.23  
CReSS_Hiccups 0.27   
CReSS_Bad breath 0.25   
CReSS_Coughing when upright  0.88  
CReSS_Coughing when lying  0.75  
CReSS_Cough after eating  0.72  
CReSS_Wheezing  0.64  
CReSS_Mucus dripping in throat 0.28 0.52  
CReSS_Excess mucus 0.26 0.52  
CReSS_Throat clearing  0.45  
CReSS_Difficulty breathing  0.45 0.26 
CReSS_Hoarseness  0.33  
CReSS_Back pain  0.24  
CReSS_Difficulty swallowing food   0.84 
CReSS_Difficulty swallowing liquids   0.73 
CReSS_Lump in throat   0.60 
CReSS_Feeling things stuck in throat   0.54 
CReSS_Decreased appetite   0.51 
CReSS_Pain in throat   0.50 
CReSS_Choking  0.32 0.47 
CReSS_Headache   0.36 
CReSS_Pressure chest 0.22  0.31 
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Cluster Analysis Appendices 
 
Figure 6-11 Two-step cluster analysis predictor importance for seven factor model with 





Figure 6-12 Two-step cluster analysis - Cluster sizes for seven factor model with 
unspecified cluster numbers 
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Figure 6-13 Two step cluster analysis with number of clusters undefined 
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F Sig. Mean Square df Mean Square df 
VOICE Factor 120.54 1 0.59 330 203.87 .000 
COUGH Factor 123.49 1 0.56 330 219.26 .000 
GI Factor 54.20 1 0.76 330 71.25 .000 
Airway_Dysphagia 
Factor 




83.25 1 0.65 330 128.66 
.000 
Life Events Factor 96.40 1 0.55 330 175.90 .000 
Lump Factor 8.32 1 0.77 330 10.83 .001 







Figure 6-15 Model summary: Two-step cluster analysis with three factors, three . 
.  
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Figure 6-16 Cluster sizes -  Two-step cluster analysis with three factors, three clusters 
 




Figure 6-18 Two-step cluster analysis with three factors, four clusters specified. 
 
158 
Table 7-7 Histograms with overlying normal curves, Skewness and Kurtosis scores for 


















Airway and Dysphagia 































Table 7-8 ANOVA table for K means cluster analysis, seven factor, three clusters 
 
Cluster Error 
F Sig. Mean Square df Mean Square df 
VOICE Factor 49.31 2 0.66 329 74.75 .000 
COUGH Factor 80.41 2 0.45 329 178.09 .000 
GI Factor 47.11 2 0.64 329 73.46 .000 
Airway_Dysphagia 
Factor 
45.80 2 0.60 329 76.21 .000 
ThroatClear_Mucus 
Factor 
48.89 2 0.61 329 80.82 .000 
Life Events Factor 61.88 2 0.47 329 132.63 .000 
Lump Factor 6.83 2 0.75 329 9.06 .000 
df, degrees of freedom; F, F-score, Sig, statistical significance 
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Figure 6-20 Two-step cluster analysis RSI, three clusters - Predictor Importance 
 
 
Table 7-9 Cluster 1: hierarchical cluster analysis for the RSI, three clusters specified 
163 
 n= Minimum Maximum Mean Std. Dev. 
RSI Hoarseness or problem 
with voice 
138 -1.48 1.59 -.23 .95 
RSI Throat Clear 138 -2.68 1.20 -.56 1.06 
RSI Excess Throat Mucus or 
PND 
138 -1.84 1.37 -.57 .98 
RSI Difficulty Swallowing 
Food Liquids or Tablets 
138 -1.04 2.06 .13 .96 
RSI Cough after Eating or 
Lying 
138 -1.32 1.74 -.53 .88 
RSI Breathing Difficulties or 
Choking Episodes 
138 -.99 2.09 -.39 .85 
RSI Troublesome Cough 138 -1.46 1.46 -.56 .90 
RSI Something Caught or 
Lump In Throat 
138 -2.44 1.03 .06 .82 
RSI Heartburn Chest Pain. 
Indigestion or Stomach Acid 
Coming Up 
138 -1.12 1.98 -.34 .88 
Std. Dev, standard deviation 
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Table 7-10 Cluster 2: hierarchical cluster analysis for the RSI, three clusters specified 
 n= Minimum Maximum Mean Std. Dev. 
RSI Hoarseness or problem 
with voice 
98 -1.48 1.59 -.35 .98 
RSI Throat Clear 98 -2.68 1.20 .20 .80 
RSI Excess Throat Mucus or 
PND 
98 -1.84 1.37 .45 .68 
RSI Difficulty Swallowing 
Food Liquids or Tablets 
98 -1.04 2.06 -.70 .62 
RSI Cough after Eating or 
Lying 
98 -1.32 1.74 -.03 .95 
RSI Breathing Difficulties or 
Choking Episodes 
98 -.99 2.09 -.26 .86 
RSI Troublesome Cough 98 -1.46 1.46 .23 .90 
RSI Something Caught or 
Lump In Throat 
98 -2.44 1.03 -.56 1.26 
RSI Heartburn Chest Pain. 
Indigestion or Stomach Acid 
Coming Up 
98 -1.12 1.98 .31 1.10 
Std. Dev, standard deviation 
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Table 7-11 Cluster 3: hierarchical cluster analysis for the RSI, three clusters specified 
 n= Minimum Maximum Mean Std. Dev. 
RSI Hoarseness or problem 
with voice 
96 -1.48 1.59 .69 .71 
RSI Throat Clear 96 -1.13 1.20 .60 .59 
RSI Excess Throat Mucus or 
PND 
96 -1.84 1.37 .37 .90 
RSI Difficulty Swallowing 
Food Liquids or Tablets 
96 -1.04 2.06 .53 .97 
RSI Cough after Eating or 
Lying 
96 -.71 1.74 .79 .65 
RSI Breathing Difficulties or 
Choking Episodes 
96 -.99 2.09 .83 .84 
RSI Troublesome Cough 96 -1.46 1.46 .58 .80 
RSI Something Caught or 
Lump In Throat 
96 -1.05 1.03 .48 .59 
RSI Heartburn Chest Pain. 
Indigestion or Stomach Acid 
Coming Up 
96 -1.12 1.98 .17 .92 







The methodology used in the thesis followed instructions from a number of statistical 
references. Where appropriate, individual statements are referenced. However, given the 
broad theme of methods described, there is considerable overlap between sources used. 
Altman DG. Practical Statistics for Medical Research. 1992. Published by Chapman and Hall, 
London. 
Costello AB., Osborne JW (2005). Best Practices in Exploratory Factor Analysis: Four 
Recommendations for Getting the Most From Your Analysis. Practical Assessment Research 
and Evaluation; 10(7). http://pareonline.net/getvn.asp?v=10&n=7 
Encyclopaedia of Biostatistics. Second Edition. Eds. Armitage & Colton. 2005. Published by 
Wiley, West Sussex, England.  
Factor Analysis and Related Techniques. Ed. M.S.Lewis-Beck. 1994. Published by Sage 
Publications Ltd.[75]   
Gaskin, J (2016), Gaskination's StatWiki. http://statwiki.kolobkreations.com . A series of 
accessible wed-based tutorial videos were useful in clarifying the approaches in SPSS to 
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